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1     Introduction 
 
 
 
1.1  Endometriosis 
 
1.1.1 General Characteristics of Endometriosis 
Endometriosis is a chronic gynaecological disorder which occurs in 10% of the 
general female population during their reproductive ages (Roger et al., 2009). It is 
characterized by uterine endometrial tissue growing outside the uterine cavity, most 
commonly in the ovary and the peritoneum. In few cases, endometriotic tissue can 
also be found on other locations, such as intestinal tract, pericardium, pleura, lung or 
brain (Giudice and Kao, 2004). Pain, menstrual disorders and infertility are the main 
symptoms of endometriosis patients. Approximately 30-50% of the patients with 
endometriosis suffer from pain (Roger et al., 2009). Endometriosis is generally 
associated with inflammation and tissue remodelling. In severe cases, it may result in 
pelvic adhesions and distortion, which could lead to infertility (Giudice and Kao, 2004).  
Non-invasive methods for diagnosis of endometriosis before surgery, such as pelvic 
ultrasound, transvirginal ultrasound (TVUS) or magnetic resonance imaging (MRI) 
are helpful for deep infiltrated endometriosis (DIE) but often fail to diagnose 
superficial lesions (Champaneria et al., 2010). Altough a lot of biomarkers were 
tested in recent years (Mihalyi et al., 2010), none of them are currently used in the 
clinical routine (May et al., 2010). Because of similar symptoms like other 
gynaecological disorders, the diagnostic time normally delays up to 6.7 years in 
average (Nnoaham et al., 2011), even though some patients still get misdiagnosis. 
Furthermore, there might be patients with pain, but without any obvious lesions of 
endometriosis. Diagnosis of endometriosis can only be achieved by laparoscopy, 
subsequently followed by tissue histological confirmation of ectopic gland formation 
with endometrial and stromal cells (Kennedy et al., 2005). However, sometimes 
(6.6%), endometriosis occurs without glands, showing only stromal cells (Boyle and 
McCluggage, 2009).  
According to the revised classification of the American Society of Reproductive 
Medicine (ASRM), four stages of endometriosis have been defined (Table 1). 
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Table1. Stages of Endometriosis 
Stage Name Description 
I 
Minimal 
endometriosis 
Only superficial lesions and possibly a few filmy adhesions 
II 
Mild 
endometriosis 
In addition, some deep lesions are present in the 
rectouterine pouch 
III 
Moderate 
endometriosis 
As above, plus presence of endometriomas on the ovary 
and more adhesions 
IV 
Severe 
endometriosis 
As above, plus large endometriomas, extensive adhesions. 
 
Endometriosis is often treated surgically, but with a recurrence rate of 5-25% after 
two years (Meuleman et al., 2011). The most widely used medical treatment of 
endometriosis involves using combined oral contraceptives, danazol, gonadotropin-
releasing hormone (GnRH) analogues and progestins (Kennedy et al., 2005; 
Vercellini et al., 2008; Kappou et al., 2010). However, most of the drug treatments 
cause undesirable side effects and are not suitable for long-term use (Kennedy et al., 
2005). Recently, dienogest, a highly selective progestin was shown to be effective 
with fewer side effects (Strowitzki et al., 2010). 
 
 
1.1.2 Pathogenesis of Endometriosis  
The exact cause of endometriosis still remains unknown. However, many theories 
have been presented to understand the etiology of endometriosis.  
The concept which is most widely accepted is the retrograde menstruation theory, 
which was first proposed by John Albertson Sampson (Sampson, 1922; 1927). He 
suggested that during menstruation, some of the endometrial tissue fragments are 
transported to the pelvic cavity through the fallopian tube. His theory is credited 
because higher volumes of refluxed menstrual blood (Halme et al., 1984) and more 
frequent myometrial contractions (Salamanca and Beltran, 1995) were observed in 
women with endometriosis, compared to healthy women.  
However, Sampson’s theory is not able to explain all causes of endometriosis. For 
example, though most women have retrograde menstrual blood flow during their 
reproductive age, not all of them develop endometriosis (Eskenazi and Warner, 
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1997). There must be other factors which contribute to the survival of ectopic 
endometrial cells and the following pathological process. Thus, the suppression of 
the immune system should not be underestimated in the pathogenesis of 
endometriosis. Physiologically the immune system should recognize the ectopic 
endometrial cells and then induce an immune response against them and finally 
destroy them. However, in pathological cases, the immune system of patients with 
endometriosis seems not to perform such a process, so that the ectopic endometrial 
cells survive ectopically (Herington et al., 2011). Dysfunction of immunity in women 
with endometriosis was demonstrated with evidence of increased abnormal B and T 
cells (Vinatier et al., 1996) and reduced activity of natural killer cells (Osuga et al., 
2011). Berbic and Fraser (2011) also showed that disturbance of regulatory T cells 
failed to recruit leukocytes to initiate effective immune responses against ectopic 
endometrial fragments in endometriosis.  
The pathogenesis of endometriosis is a complex process associated with various 
factors. To better understand the process of endometriosis, Omwandho et al. (2010) 
summarized its process and categorized it into six stages, which will be described in 
a later paragraph (1.2.5).   
 
 
1.1.3 In vivo Models of Endometriosis 
According to the most widely accepted theory for the pathogenesis of endometriosis, 
the implantation of retrograde endometrial tissues is essential for the establishment 
of peritoneal endometriosis. Because of that, spontaneous menstruation, which only 
occurs in human and primates, is required in the pathogenesis of endometriosis. 
However, it is quite difficult to compare humans and primates because of species 
specificity. Recently, Dehoux et al. (2011) questioned the baboon model because of 
the low rate of spontaneous endometriosis (4.8%) and induced endometriosis 
(27.6%).  
In recent years, nude or severe combined immune deficiency (SCID) mice, with 
transplanted human endometrial tissue, have been used as models for the study of 
endometriosis (Grümmer, 2006; Liu et al., 2010; Katayama et al., 2010; Becker et al., 
2011). These models showed that human endometrial and endometriotic tissue or 
cells grafted into the peritoneal cavity of immunodeficient mice were able to implant 
and to develop into endometriotic lesions. Furthermore, in such models, the 
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peritoneal environment or the physical condition of the hosts can be changed, 
according to the aim of the studies. Tabibzadeh et al. (1999) reported that peritoneal 
fluid from patients with endometriosis increased the implantation of the human 
endometrial tissue in the mouse model. These investigations confirm that the 
immunodeficient mouse model with implantation of human endometrial tissue is an 
appropriate method for the study of endometriosis.  
However, the SCID mouse model also has disadvantages. Because of the lack of the 
immune system, the mice often die within a short lifespan. More importantly, 
endometriosis is a disease in which the immune system is highly involved. Thus, the 
immunodeficient mouse model has also limitations in the study of endometriosis.  
 
1.1.4 In vitro Models of Endometriosis 
The primary advantage of in vitro models is that it simplifies the system, so that the 
investigators can focus on a small number of components, especially the 
investigation on intracellur proteins and pathways is more easily achieved. 
For in vitro models of endometriosis, endometrial and endometriotic tissues are 
obtained directly from patients after surgical treatment or from in vivo models. For cell 
culture, the primary epithelial or stromal cells are isolated and then kept in cell culture. 
The invasiveness of endometriotic cells was provn in vitro with the collagen invasion 
assay (Gaetje et al., 1995; Starzinski-Powitz et al., 1998), which showed the 
possibility to study endometriosis in vitro. However, this technique has disadvantages 
and restrictions. For example, primary endometrial cell cultures usually contain 
heterogeneous cell types and die after few passages (Starzinski-Powitz et al., 1998).  
 
The establishment of immortalized endometrial and endometriotic cell lines 
overcomes this problem. Starzinski-Powitz et al. (1998) established immortalized 
endometriotic cell lines, which could be kept in culture for 40 passages, by inducing 
the expression of the SV40 T antigen, a viral oncogene. In addition, cell lines used 
for studies of endometriosis should be similar to primary endometriotic cells, e.g. 
should express estrogen and progesterone receptors, which are also expressed in 
primary endometriotic cells (Segars, 1997). 
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1.2  Transforming Growth Factor-beta  
 
1.2.1 General Characteristics of Transforming Growth Factor-beta 
The transforming growth factor-beta (TGF-β) family is a group of secreted proteins 
which comprises three isoforms, TGF-β1, TGF-β2 and TGF-β3. This subfamily 
belongs to a group of growth factors called transforming growth factor β superfamily, 
which also includes the bone morphogenetic protein (BMP) subfamily, the 
inhibin/activin subfamily and the growth differentiation factor (GDF) subfamily (Peng, 
2003).  
The biological functions of TGF-βs are multiple. They regulate many aspects of cell 
functions, such as proliferation, differentiation, apoptosis, and cell motility in diverse 
cell types. They are also involved in many biological processes, such as 
morphogenesis, embryonic development, immune regulation, wound healing, 
inflammation and tumorigenesis (Kaminska et al., 2005; Padua and Massagué, 2009; 
Taylor, 2009; Santibañez et al., 2011). 
All three isoforms are secreted in a latent form containing the TGF-β homodimer 
(Derynck et al., 1985), which binds the latency associated peptide (LAP), forming a 
complex called small latency complex (SLC). This complex is released and stored in 
the ECM after binding to latent-TGF-β binding proteins (LTBPs) (Rifkin, 2005).  
The biological functions of the TGF-βs have been studied through gene knockout 
techniques. TGF-β1 knockout mice die at midgestation due to defective 
haematopoiesis and vasculogenesis (Dickson et al., 1995), and the few survivors 
show an altered immune response (Koglin et al., 1998), or decreased bone mass 
(Geiser et al., 1998), or propensity to colon cancer (Engle et al., 2002). TGF-β2 
knockout mice demonstrate multiple malformation defects (Sanford et al., 1997) and 
impairment of central synapse function (Heupel et al., 2008). TGF-β3 knockout mice 
die shortly after birth due to defective palate growth (Taya et al., 1999) and delayed 
lung development (Shi et al., 1999). 
The receptors of the TGF-βs are single pass serine/threonine kinase receptors which 
exist in three isoforms with distinct structural and functional properties (Chang et al., 
2002). TGF-β receptor type I (TβRI) and type II (TβRII) have similar binding affinity 
which is high for TGF-β1 and -β3, but low for TGF-β2.  The type III (TβRIII) receptor 
shows high affinity to all three isoforms (Gordon et al., 2008). Typical TGF-β 
signaling starts with binding of the ligands to the TβRII, which phosphorylates the 
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TβRI. Then TβRI subsequently phosphorylates the C-terminus of Smad2 and/or 
Smad3, leading to downstream signal transduction (Wrighton et al., 2009).  
 
 
1.2.2 Smad Pathway in TGF-β Signaling 
The Smad proteins are the most important intercellular proteins, which transduce the 
extracellular signals from the TGF-β receptors to the nucleus (Massagué, 1998). 
There are three different types of Smads. The receptor-regulated Smads (R-Smads), 
including Smad1, 2, 3, 5 and 8, interact with the common-mediator Smad (co-Smad, 
Smad4), which is necessary for the downstream signaling as a heteromeric partner of 
the R-Smads. Smad6 and Smad7 are inhibitory Smads (I-Smads), which inhibit the 
activity of R-Smads and co-Smad (Padgett et al., 1998). In general Smad2 and 
Smad3 are phosphorylated by receptors of TGF-βs or activin (Shimizu et al., 1998), 
while Smad1, 5 and 8 are phosphorylated by the BMP type I receptor (Aoki et al., 
2001).   
The basic TGF-β induced Smad-pathway is shown in Figure 1 (Massagué, 2000). 
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Figure 1. The basic Smad pathway (Massagué, 2000) 
TβRI is activated by TβRII when TGF-βs induces the association of TβRI and TβRII. 
Then R-Smads are phosphorylated, and together with the co-Smad assemble 
transcription regulatory complexes. However, to be accessible to membrane 
receptors, R-Smads are tethered in the cytoplasm by Smad anchor for receptor 
activation (SARA). The phosphorylation of R-Smads decreases the affinity of R-
Smads for SARA and increases their affinity for co-Smads. The resulting Smad 
complex is free to move into the nucleus and competent to associate with 
transcriptional co-activators or co-repressors. 
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1.2.3 Smad-independent Pathways in TGF-β Signaling 
The identification of non-Smad signalling proteins that participate in TGF-β signal 
transduction pre-dates the discovery of the Smads (Yue and Mulder, 2000). Zhang 
(2009) summarized the Smad-independent pathways, which reinforce or modulate 
the signal transduction of the TGF-βs. Most of the studies on Smad-independent 
pathways were performed in cell models in vitro. The small GTPase Ras, the 
extracellular signal-regulated kinases (ERKs), p38 mitogen-activated protein kinase 
(p38 MAPK) and c-Jun N-terminal kinases (JNKs) are found to be implicated in TGF-
β signaling (Yue and Mulder, 2000).  
These Smad-independent pathways provide other possibilities of TGF-β signal 
transduction without the participation of the Smads. For example, TβRI can directly 
phosphorylate ShcA, which induces the association with growth factor receptor-
bound protein-2 (GRB2) and son of sevenless (SOS), then leading to sequentially 
activation of Ras, Raf, MEK1/2 and ERK1/2 (Lee et al., 2007). Besides, TGF-β can 
activate the Ras cascades through the activation of p21 activated kinase-2 (PAK2) 
(Suzuki et al., 2007). These data suggests that TGF-β can directly activate the ERKs 
without participation of the Smad pathway. 
Furthermore, these Smad-independent signal proteins have been suggested to 
interact with the Smad pathway (Massague et al., 2000; Moustakas and Heldin, 
2005). The ERK pathway can lead to direct phosphorylation of R-Smads, thus 
blocking their nuclear translocation and transcriptional output (Kretzschmar et al., 
1997). The p38 substrate kinase, MSK1 (mitogen and stress activated protein kinase-
1) regulates the transcriptional activity of Smad3 by promoting its association with the 
co-activator p300 (Abécassis et al., 2004). In addition, TGF-β-activated JNK 
phosphorylates Smad3 and induces its nuclear translocation and transcriptional 
activity (Engel et al., 1999). 
 
 
1.2.4 TGF-βs in the Normal Endometrium 
TGF-βs are differentially and stage-specifically expressed in the endometrium during 
the menstrual cycle (Figure 2). According to the results from Gaide Chevronnay et al. 
(2008), the mRNA and protein expression of TGF-β1 was the highest, which was 2.5-
fold higher than TGF-β2 and 20-fold higher than TGF-β3. Because of their high 
expression, TGF-βs are suggested to participate in the biological processes during 
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menses, such as tissue breakdown and uterine contraction (Omwandho et al., 2010).  
Menses Proliferative phase Secretory phase
estrogen
progesterone
 
Figure 2. Levels of TGF-βs in human endometrium and hormonal changes during 
the menstrual cycle. Only the strongest expression of the TGF-βs is shown. All three 
isoforms are highly expressed during menses (Omwandho et al., 2010). 
 
 
1.2.5 TGF-βs in Endometriosis 
TGF-βs are suggested to be crucial in the pathogenesis of endometriosis because 
they are highly detected in the serum and peritoneal fluid of women with 
endometriosis (Pizzo et al., 2002). The process of endometriosis can be categorized 
into six stages (Omwandho et al., 2010), including cell shedding and reflux, cell 
survival, immune suppression, cell adhesion and invasion, angiogenesis, and 
bleeding. TGF-βs are involved directly or indirectly in most of these stages. 
According to Sampson’s theory, endometriosis originates from retrograde 
endometrial tissue. Thus, shedding and reflux of endometrial cells are the 
prerequisites for the establishment of endometriosis. The highest expression of TGF-
βs was detected during menses (Gaide Chevronnay et al., 2008), coincident with cell 
shedding, thus suggesting the possible involvement of the TGF-βs in cell shedding. 
Furthermore, abnormal myometrial contractions with higher frequencies were 
described in women with endometriosis, and were suggested to be associated with 
the increased dissemination of endometrial fragments (Bulletti et al., 2002, 2004). 
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Although involvement of TGF-βs in uterine contractions still needs to be further 
investigated, TGF-βs were shown to induce the contraction of endometrial stromal 
cells (Nasu et al., 2005). 
TGF-βs regulate cell survival by regulating cell proliferation and apoptosis. However, 
these effects are extremely dependent on the cell types and the cellular context. For 
example, TGF-βs trigger apoptosis in epithelial cells, but induce proliferation in 
fibroblasts (Rahimi and Leof, 2007). With respect to endometrial cells, TGF-βs 
showed different effects on regulation of cell proliferation, compared to cells from 
other organs. TGF-β1 stimulated proliferation of low epithelial cell numbers, but 
inhibited it at high cell numbers in women with and without endometriosis (Meresman 
et al., 2003). All three TGF-β isoforms inhibited the proliferation of endometrial 
stromal cells dose-dependently (Nasu et al., 2005).  
After endometrial fragments enter the peritoneal cavity, the escape from the immune 
attack is important for their survival. TGF-β1 can strongly suppress the immune 
system, which was demonstrated by lethal multi-organ inflammation in gene knockout 
mice (Shull et al., 1992). In addition, TGF-βs suppressed proliferation and 
differentiation of lymphocytes including cytolytic T cells, natural killer cells and 
macrophages (Pardali and Moustakas, 2007). Blocking TGF-β1 function increased 
the levels of IFN-γ and IL-10, which are secreted by natural killer cells derived from 
human endometrium (Eriksson et al., 2004). Thus, high levels of TGF-βs may trigger 
immune escape, which might decrease the response of natural killer cells to the 
ectopic tissues. All in all, TGF-β might increase the survival potential of ectopic 
endometrial fragments by suppressing the immune system.  
The process of cell-to-ECM adhesion is mainly regulated by integrins, which connect 
cells to the ECM (Witz et al., 2003). Koth et al. (2007) showed that integrins can 
activate latent TGF-β1. However, so far there is no evidence that TGF-βs could affect 
cell adhesion directly. The regulation might be indirect, by regulating the balance of 
matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases 
(TIMPs). MMPs are a goup of proteinases which degrade the ECM. TIMPs are the 
natural inhibitors of MMPs. The balance of MMPs and TIMPs regulates cell adhesion 
by controlling degradation and remodeling of the ECM (Bourboulia and Stetler-
Stevenson, 2010). The regulation of MMPs and TIMPs by TGF-βs will be introduced 
in the following paragraph. 
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Conclusively, TGF-βs may be involved in most of the biological processes of the 
establishment and/or maintenance of endometriosis. However, the exact role remains 
to be studied further and clarified. 
 
 
1.3  Matrix Metalloproteinases 
Matrix Metalloproteinases are a subfamily of metalloproteases, which consists of 23 
distinct proteases in humans (Table 2). They are zinc- and calcium-dependent 
enzymes, involved mainly in ECM degradation, as well as in some other biological 
functions (Borkakoti, 2000; Bode and Maskos, 2003; Klein and Bischoff, 2011). The 
newly synthesized MMPs mainly exist in the form of proenzymes without proteolytic 
activities. The pro-MMPs can be activated by other MMPs or serine proteinases like 
plasmin or oxidants. However, the mechanism of activation for most pro-MMPs 
remains unknown (Ra and Parks, 2007). 
Gelatinase A (MMP-2) is one of the most important MMPs in ECM degradation. It is 
primarily secreted by fibroblasts during tissue development and regeneration 
(Morgunova et al., 1999). Together with gelatinase B (MMP-9), it degrades type IV 
collagen, gelatin (denatured collagen) and other types of collagen (V, VII and X), as 
well as elastin and fibronectin (Klein and Bischoff, 2011).  
Tissue inhibitors of metalloproteinases are characterized as natural inhibitors of 
MMPs. So far, four TIMPs (-1, -2, -3 and -4) have been identified. They inhibit the 
activity of MMPs by forming TIMP-MMP complexes (Brew and Nagase, 2010). Thus, 
the balance between activated MMPs and TIMPs plays an essential role in regulating 
ECM degradation and remodeling.  
In the human endometrium, MMPs and TIMPs are mainly secreted by stromal cells 
(Salamonsen and Woolley, 1996). In addition, macrophages are also able to secrete 
large amounts of various MMPs (Goetzl et al., 1996). The expression of most MMPs 
is repressed during the secretory phase and increases dramatically at or slightly 
before menstruation (Vassilev et al., 2005). With respect to endometriosis, the 
degradation of the ECM by MMPs results in the cell shedding during menstruation 
and thus might contribute to the invasiveness of ectopic endometrial cells (Juhasz-
Böss et al., 2010).  
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Table 2 
Overview of the identified human matrix metalloproteinases 
MMP Alternative Name MMP Alternative Name 
1 Collagenase-1 16 Membrane type-3 MMP 
2 Gelatinase A 17 Membrane type-4 MMP 
3 Stromelysin-1 19 None 
7 Matrilysin 20 Enamelysin 
8 Collagenase-2 21 None 
9 Gelatinase B 23 Femlysin 
10 Stromelysin-2 24 Membrane type-5 MMP 
11 Stromelysin-3 25 Membrane type-6 MMP 
12 Macrophage metallo-elastase 26 Matrilysin/endometase 
13 Collagenase-3 27 None 
14 Membrane type-1 MMP 28 Epilysin 
15 Membrane type-2 MMP  
 
Both MMPs and TIMPs can be regulated by TGF-βs. In the human endometrium, 
TGF-βs show a dual effect in regulating MMPs, which suppress the synthesis of 
MMP-3 and MMP-7 (Bruner et al., 1995), but increase the expression of MMP-2 and 
MMP-9 (Hirata et al., 2003). In human myometrial smooth muscle cells, TGF-β1 
decreases the mRNA and protein synthesis of MMP-1 and MMP-3, whereas the 
mRNA and protein synthesis of TIMP-1 is increased (Ma and Chegini, 1999). 
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1.4  Plasminogen Activator Inhibitor-1 
Plasminogen activator inhibitor-1 is the primary inhibitor of tissue plasminogen 
activator (tPA) and urokinase (uPA), the activators of plasminogen (Czekay and 
Loskutoff, 2004). The main function of PAI-1 is to inhibit the tPA and/or uPA induced 
fibrinolysis, and hence accelerates the progression to fibrosis (Binder et al., 2002). 
PAI-1 can be regulated by growth factors, cytokines and hormones, among which 
TGF-β1 is the most important one, because the PAI-1 promoter contains three Smad 
binding elements (SBEs), the main response elements of TGF-β signaling (Binder et 
al., 2002).  
PAI-1 is mainly produced by endothelial cells, and released into the plasma. However, 
PAI-1 can be expressed and synthesized in various cell types (Binder et al., 2002). 
With respect to endometrial and endometriotic tissues, Bruse et al. (1998, 2004) 
showed that the expression of PAI-1 and uPA is much higher in the endometriotic 
tissue and endometrial tissue of women with endometriosis, compared to tissue of 
women without endometriosis. Also the PAI-1 level was higher in ectopic tissues than 
in eutopic tissues of the same woman (Bruse et al., 2004). Czekay et al. (2003, 2011) 
showed that cell migration was regulated by uPA and its high affinity receptor, uPAR. 
They demonstrated that PAI-1 perturbed the cell attachment to the ECM by inhibiting 
uPAR-vitronectin and integrin-vitronectin interactions, and thus facilitated cell 
migration by regulating ECM proteolysis. Furthermore, PAI-1 is able to inhibit the 
activity of MMPs, by inhibiting plasmin. However, this inhibition only affected the 
activity of MMP-1 and MMP-3 (Murphy et al., 1999), but had no effect on the activity 
of gelatinases (MMP-2 and MMP-9) (Ramos-DeSimone et al., 1999). Thus, in 
conclusion, PAI-1 might be an important protein in the pathogenesis of endometriosis. 
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1.5  Objectives 
Though TGF-βs has been strongly suggested to be involved in the pathogenesis of 
endometriosis, the exact functions remain to be clarified. TGF-βs are strong 
regulators of cell growth, but extremely cell type- and context-dependent. Recent 
studies showed that the regulation of cell proliferation by TGF-β in endometrial and 
endometriotic cells seems to be different from cells from other organs, and it is still 
not clear whether TGF-βs increase or reduce the number of endometrial and 
endometriotic cells. Furthermore, TGF-βs are able to regulate other proteins, like 
MMPs and PAI-1, which contribute to the etiology of endometriosis as well. Thus, it is 
also important to understand how TGF-βs regulate these proteins and the pathways 
through which the regulation proceeds. 
The immortalized endometriotic cell lines used in this study have been well 
characterized and proven to be sufficient in studying endometriosis. Together with 
endometrial cell lines, we were able to generate a reliable in vitro model, in order to 
study the basic aspects of endometriotic cells and their differences from normal 
endometrial cells, as well as the functions of TGF-βs and their signaling pathways in 
endometrial and endometriotic cells. 
Conclusively, the aim of this study was to investigate some aspects of the biological 
functions of TGF-βs, such as influence on cell numbers and regulation of some 
proteins, which are important in endometriosis, as well as to study the signaling 
pathway of TGF-βs in endometrial and endometriotic cells in vitro. Also, the different 
characteristics of normal endometrial cells and endometriotic cells will be 
documented. 
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2    Materials and Methods 
 
 
 
2.1 Human Immortalized Endometrial and Endometriotic Cell Lines 
 
2.1.1 Endometrial Epithelial and Stromal Cells 
The HES cells are a spontaneously immortalized human endometrial epithelial cell 
line (Fig. 3). The HES cells express both cytokeratin and vimentin, and secrete no 
prolactin after progesterone stimulation, which strongly support their epithelial 
phenotype (Desai et al., 1994).  
 
 
Figure 3. Human endometrial epithelial HES cells. The HES cells show a typical 
shape of epithelial cells in vitro. The cells appear as triangular, flat plates and 
aggregate closely, which indicates epithelial cell-to-cell contacts. The HES cells 
normally form flat monolayers in vitro. 
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The THESC cells (CRL-4003, ATCC) (Fig. 4) are telomerase immortalized 
endometrial stromal cells (Krikun et al., 2004). The estrogen receptor and the 
progesterone receptor are strongly expressed in THESC (Banu et al., 2008). The 
cells undergo decidualization when exposed to MPA (medroxyprogesterone 17-
acetate) plus estrogen (Krikun et al., 2004).  
 
 
Figure 4. Human endometrial stromal THESC cells. The THESC cells are elongated 
spindle-shaped in vitro. Their size is larger compared to epithelial cells. The cells are 
often disjointed and scattered when their numbers are few. However, when crowded, 
they often aggregate in parallel clusters. Unlike HES cells, THESC cell do not form 
flat monolayers in vitro. 
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2.1.2 Endometriotic Epithelial and Stromal Cells 
The 12Z cells are SV40 immortalized (Fig. 5). They are epithelial-like endometriotic 
cells expressing cytokeratins, vimentin and E-Cadherin that are typically found in the 
endometrial tissue (Zeitvogel et al., 2001) Furthermore, 12Z cells express the 
estrogen receptor α and β, as well as the progesterone receptor (Banu et al., 2008). 
 
 
Figure 5. Human endometriotic epithelial 12Z cells. The 12Z cells have a typical 
epithelial cell shape in vitro. The cells have a similar appearance as HES cells - 
triangular, flat plates aggregating closely to each other, which suggests epithelial cell-
to-cell contacts. The 12Z cells normally form a flat monolayer in vitro. 
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The 22B cells are SV40 immortalized (Fig. 6). They are stromal-like endometriotic 
cells and are vimentin-positive, but cytokeratin and E-Cadherin negative (Zeitvogel et 
al., 2001). The estrogen receptors α and β are strongly expressed in 22B cells. 
However, the progesterone receptor mRNA is nearly undetectable (Banu et al., 2008). 
 
 
Figure 6. Human endometriotic stromal 22B cells. The 22B cells are elongated 
spindle-shaped cells. Some of them have a branched cytoplasm. The size of 22B is 
larger compared to THESC cells. Like THESC cells, the 22B cells are disjointed and 
scattered when their numbers are few and often aggregate in parallel clusters when 
crowded.   
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2.2 Cell Culture with Endometrial and Endometriotic Cell Lines 
 
2.2.1 Aseptic Techniques for Cell Culture 
All equipments and solutions needed for cell culture were either purchased sterile or 
sterilized in an autoclave. Solutions which are not thermoduric were sterilized using 
sterile filters with a pore size of 0.22 µm (disposable filter units, Millipore). The 
surface of the laminar flow bench was wiped with 70% alcohol. Then the UV light in 
the laminar was put on for 20 minutes before starting to work. All handling was 
performed under the laminar flow bench in order to guarantee sterile conditions. 
Equipment was also cleaned with 70% alcohol before taken into the laminar flow 
bench. Hands were protected with latex gloves and cleaned with 70% alcohol, before 
starting to work at the laminar flow bench. 
The media used in cell culture were supplemented with 1% pen/strep (100X, PAA, 
Austria) and 1% plasmocin in order to protect cells against bacteria and mycoplasms. 
To minimize contamination, medium transfer was performed using sterile disposable 
pipettes. The bottle necks of the cell culture flasks were cleaned with sterile cotton 
swabs after medium transfer. 
 
 
2.2.2 Medium Preparation 
Cell culture medium provided the environment and necessary nutrients required in 
cell culture. In general, media were supplemented with an adjusted amount of serum, 
antibiotics and nutrients. Ready-to-use media were prepared previous of the work 
with cells. To ensure the medium retaining sterile, all procedures were done under 
the laminar flow bench. 
 
 
 
• Medium for endometrial and endometriotic epithelial cells: 
   DMEM High Glucose (4.5 g/L) without phenol red (PAA, Austria) 
      + 10% fetal calf serum (FCS) (PAA, Austria) 
      + 1% L-glutamine (PAA, Austria) 
      + 1% 100x pen/strep (PAA, Austria) 
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• Medium for endometrial stromal cells: 
   DMEM F12 with L-glutamine without phenol red (Invitrogen, U.S.A.) 
      + 10% fetal calf serum  
      + 1% Insulin Transferrin Selenium X (Invitrogen, U.S.A.) 
      + 1% 100x pen/strep 
 
• Medium for endometriotic stromal cells: 
      DMEM High Glucose (4.5 g/L) without phenol red 
         + 10% Charcoal/Dextran Treated FCS (Thermo Scientific, U.S.A.) 
         + 1% L-glutamine 
         + 1% 100x pen/strep 
 
The ready-to-use medium was stored at 4°C by a maxi mum of 45 days. Aliquots 
were pre-warmed to 37°C in a water bath before use.   
 
 
2.2.3 Medium Change 
The medium in the cell culture flask was replaced with fresh medium every 2-3 days 
under the laminar flow bench. Medium was pre-warmed in a water bath (37°C) for 20 
minutes prior to use. Sterilized and disposable pipette tips were used during the 
whole process. The old medium was discarded and fresh medium was added. The 
date of medium change was recorded on the flask after replacement. Then the flasks 
were taken back to the cell culture incubator. 
 
 
2.2.4 Cell Passage 
Cell passage is a technique that keep cells alive and growing under cultured 
conditions for extended periods of time. Cells were passaged when they are 70%-
80% confluent. Medium and accutase (PAA, Austria) were pre-warmed in a 37°C 
water bath for 20 minutes. Old medium was discarded with a disposable pipette tip. 
Then 10ml accutase was added and cells were incubated in the cell culture incubator 
(37°C, 5% CO 2) for 5 to 10 minutes. After that, a microscope was used to ensure that 
cells were completely detached from the cell culture flask. Then 10 ml fresh medium 
was added to neutralize the accutase. The cell suspension was transferred into a 50 
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ml falcon tube, centrifuged for 5 minutes at 1500 x g. The liquid phase was discarded. 
Fresh medium (5 ml) was added to re-suspend cell pellets. One part of the cell 
suspension (500 µl to 2 ml) was transferred into a new cell culture flask with 25 ml 
fresh medium. The date of passage was written down on the flask. Then the flask 
was taken back into the cell culture incubator. 
 
 
2.2.5 Cell Freezing   
Cryopreservation was performed to maintain the cells for longer periods. The cell 
pellet was obtained by following the process of cell passage (2.2.4). Instead of 
resuspending the cells in culture medium, cells were resuspended in medium with 
Filocethplus (Procryoptect, Germany), cryo-medium with low DMSO which protected 
cells from the extremely low temperature and was less toxic to the cells compared to 
older standard procedures with 20% DMSO. Aliquots of 1ml cell suspensions are 
transferred into cryotubes. These cryotubes are then stored at -80°C for 4-6 hours 
before finally preserved in liquid nitrogen. 
 
 
2.2.6 Cell Thawing 
Cells were stored with 1 ml Filocethplus in cryotubes in liquid nitrogen (-196°C) for 
long term preservation. For thawing, the cryotubes were taken out of the liquid 
nitrogen and placed into a 37°C water bath. As soon  as the ice in the cryotube was 
completely thawed (approx. 2 to 5 minutes), cells were transferred to a 15 ml falcon 
tube with 9 ml fresh cell culture medium. The liquid phase was discarded after 
centrifugation (1500 x g, 5 min) to remove the DMSO. The remaining pellet was 
resuspended with 1 ml medium. Then the cell suspension was transferred into a 75 
cm² or 150 cm² cell culture flask containing 14 ml or 24 ml medium, respectively. 
Mycokill AB (PAA, Austria) was added into the flasks to protect cells from 
microorganisms. The cell culture flasks were incubated in a cell culture incubator 
(37°C, 5% CO 2). 
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2.2.7 Cell Counting 
When measuring the cell numbers in cell culture flasks, cells were detached and 
resuspended as described in section 2.2.4. Then one part of the cell suspension (100 
µl) was transferred to a CASY tube with 10 ml CASY-ton solution and mixed well. 
Then the cells were measured with the CASY-counter (Schaerfe System, Germany).  
 
When measuring the cell number from cell culture plates, accutase was given 
according to the size of the plates (500 µl for 6-well plates, 200 µl for 24-well plates). 
After cells were completely detached from the plate, equal volumes of fresh medium 
was added and cells were resuspended thoroughly. Then 10 µl cell suspension was 
transferred to a CASY tube with 10 CASY-ton solution and mixed well. Then the cell 
numbers were determined with the CASY-counter.  
  
 
2.2.8 Cell Seeding 
After the cell numbers from the cell culture flasks were determined, cells were 
transferred into cell culture plates or dishes. In the experiments described here, 
3x104 cells were seeded into each well of a 24-well cell culture plate (TPP, 
Switzerland) with 1 ml medium containing 10% FCS, 3x105 cells were seeded into 
each well of a 6-well cell culture plate (TPP, Switzerland) with 4 ml medium 
containing 10% FCS, and 1x106 cells were seeded in a 60 mm cell culture dish (TPP, 
Switzerland) with 5 ml medium containing 10% FCS. The plates or dishes were 
cultured overnight (37°C, 5% CO 2).  
 
 
2.2.9 Cell Starving 
After culturing overnight, the old medium was discarded. Then fresh medium 
containing 1% FCS was added to starve the cells.   
 
 
2.2.10 Stimulations with TGF-βs 
•  rh-TGF-β1 and rh-TGF-β2 (Promokine, Germany)  
stock concentration=25 µg/ml 
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Medium containing 1% FCS with the desired concentration of TGF-β1 or TGF-β2, 
respectively, was prepared. Then the old medium was removed and the medium with 
TGF-β1 or TGF-β2 was added into the appropriate wells, respectively. PBS was 
added into the control well. After that, cells were cultured in the cell culture incubator 
(37°C, 5% CO 2). 
 
 
2.3 Determination of Cell Numbers after Stimulation with TGF-βs 
To analyze how TGF-β1 and TGF-β2 affect the cell numbers, the cell numbers were 
measured after the stimulation with TGF-β1 or TGF-β2. Three different 
concentrations of TGF-β1 or TGF-β2 (1 ng/ml, 5 ng/ml, 10 ng/ml) were used to test 
the dose-dependency. The procedure is described briefly in Figure 7. Three 
independent experiments were performed. Statistical analysis was done by using a 
statistic software (GraphPad InStat 3). 
 
 
 
 
 
 
 
Culture 3x104 cells with 1ml medium (10% FCS) in 24-well plate 
Replace medium (10% FCS) with medium (1% FCS) 
 
Stimulate cells 
with TGF-β1  
Stimulate cells 
with TGF-β2  
8 hours 
72 hours 
Cell counting 
Figure 7. Determination of cell numbers after stimulation with TGF-βs  
Add PBS as 
negative control  
over night 
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2.4 Analysis of MMP-2, MMP-9 and PAI-1 Secretion  
To analyze how TGF-β1 and TGF-β2 influence MMP-2, MMP-9 and PAI-1 secretion, 
MMP-2, MMP-9 and PAI-1 ELISAs were performed. The procedure is described 
briefly in Figure 8. Three independent experiments were performed. Statistical 
analysis was done by using a statistic software (GraphPad InStat 3).  
 
 
 
 
 
 
 
 
 
Seed 3x105 cells in 6-well plates with 4 ml medium (10% FCS) 
Add Inhibitors, respectively 
- LY364947 
- SB203580 
- ERK inhibitor II 
Add TGF-β1 or TGF-β2 (10ng/ml), respectively 
Collect supernatants Cell Counting 
MMP-2, -9 or PAI-1 ELISA 
 6 hours  
 over night 
Replace medium (10% FCS) to medium (1% FCS) 
 2 hours  
 72 hours  
Figure 8. Scheme for analyzing the secretion of MMP-2 and PAI-1  
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2.4.1 Cell Culture with Intracellular Pathway-specific Inhibitors  
To investigate the pathways that might be involved in TGF-β signaling, three 
inhibitors targeting different pathways were used. 
•  TGF-β receptor type I inhibitor: LY364947 (Sigma-Aldrich, USA) (Sawyer et al., 
2003) 
•  p38/MAPK inhibitor: SB203580 (Cayman, USA) (Roux and Blenis, 2004) 
•  ERK inhibitor: ERK inhibitor II (Merck, Germany) (Ohori et al., 2005)  
Media with 1% FCS containing 5 µM LY364947, 5 µM SB203580 or 20 µM ERK 
inhibitor II, respectively, were prepared. Media in 6-well culture plates were removed. 
Then 2ml medium with or without inhibitor was added into the corresponding wells, 
respectively. DMSO was added into wells without inhibitor as vehicle, because all 
inhibitors are dissolved in DMSO. Then cells were incubated for 2 hours (37°C, 5% 
CO2). Then cells were stimulated with 10 ng/ml TGF-β1 or TGF-β2 as described in 
section 2.2.10. 
 
 
2.4.2 Collection of supernatants and Cell Counting 
Supernatant (1 ml) from each well was collected in a 1.5 ml microcentrifuge tube. 
Then 7µl Protease Inhibitor cocktail (Sigma-Aldrich, USA) was added into each tube 
in order to protect proteins against proteases. The supernatants were centrifuged 
(5000 x g, 10 min. at 4°C). Then 900 µl supernatant from each tube was collected 
and stored as three aliquots at -20°C. 
After the collection of supernatants, cell numbers of each well were determined as 
described in section 2.2.7.  
 
 
2.4.3 MMP-2 and MMP-9 ELISAs 
MMP-2 or MMP-9 levels in the supernatant were measured by using MMP-2 or MMP-
9 ELISA kits (R&D Systems) detecting total (active and inactive) MMPs, respectively.   
The kits contained: 
• Total MMP-2 or MMP-9 Microplate – 96-well polystyrene microplate (12 strips of 8 
wells) coated with a polyclonal antibody against human MMP-2 or MMP-9 
• Total MMP-2 or MMP-9 Conjugate – polyclonal antibody against human MMP-2 or 
MMP-9 conjugated to horseradish peroxidase, with preservatives 
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• Total MMP-2 or MMP-9 Standard – recombinant human pro-MMP-2 or pro-MMP-9 
in a buffered protein with preservatives, lyophilized 
• Assay Diluent RD1-74 – a buffer with preservatives 
• Calibrator Diluent RD5-32 – a buffer with preservatives 
• Wash Buffer Concentrate – a 25-fold concentrated solution of buffered surfactant 
with preservatives 
• Color Reagent A – stabilized hydrogen peroxide 
• Color Reagent B – stabilized chromogen 
• Stop Solution – 2M sulfuric acid 
 
Reagent Preparation 
All reagents were brought to room temperature before use. 
• Wash Buffer – 20 ml of Wash Buffer Concentrate is diluted with 480 ml deionized 
water. 
• Substrate Solution – Color Reagent A and B are mixed together in equal volumes 
and protected from light within 15 minutes of use. 
• Standard – The MMP-2 or MMP-9 standard was reconstituted with 1ml deionized 
water to get a stock solution of 100 ng/ml. The standard was kept at room 
temperature for at least 15 minutes with gentle agitation. Meanwhile, 7 EP tubes with 
200 µl Calibrator Diluent RD5-32 were prepared. Then 200 µl standard stock solution 
was used to produce dilution series (50 ng/ml, 25 ng/ml, 12.5 ng/ml, 6.25 ng/ml, 3.12 
ng/ml, 1.56 ng/ml and 0.78 ng/ml). The Calibrator Diluent RD5-32 served as standard 
of 0 ng/ml. 
• Supernatant Sample – Supernatants stored at -20°C were thawed at room  
temperature. Supernatants collected from THESC and 22B were 5-fold diluted with 
Calibrator Diluent RD5-32 for MMP-2 measurement because the concentration of 
MMP-2 in these supernatants was outside the detectable range. The samples from 
the other cell lines were not diluted. All samples were mixed thoroughly before use. 
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Assay Procedure  
All reagents and samples were brought to room temperature before use. All samples, 
standards and controls were assayed in duplicate. The procedure of the assay is 
described in Figure 9. 
 
Prepare the reagents and samples as described above 
Add 50µl standard, control or sample to each well. 
Aspirate each well and wash with 400µl wash buffer. 
Repeat 3 times. 
Add 200µl Conjugate solution to each well.  
Aspirate each well and wash with 400µl wash buffer. 
Repeat 3 times. 
Add 100µl Assay Diluent RD1-74 to each well 
 Incubate 2 hours on orbit shaker at RT  
 Incubate 2 hours on orbit shaker at RT  
Add 200µl Substrate Solution to each well. 
Incubate 30 min.  
Protect from light.  
Add 50µl Stop Solution to each well. 
 within 30 min. 
Measure the OD values at 450nm on a 
microplate reader, with the correction 
wavelength at 570nm. 
Figure 9. Scheme of MMP-2 or MMP-9 ELISAs 
 28 
2.4.4 PAI-1 ELISAs 
The PAI-1 level in the supernatants was measured by using a TECHNOZYM® PAI-1 
Antigen ELISA Reagent Kit (Technoclone, Germany).  
The kit contained: 
• Coating Antibody – 500 µg lyophilized monoclonal anti-PAI-1 
• Conjugate monoclonal anti-PAI-1 
• Calibrator 
 
Reagents Preparation 
All reagents were brought to room temperature before use. 
• Phosphate buffered saline (PBS) – 8.0 g NaCl, 0.2 g KCl, 0.2 g KH2PO4, 1.44 g 
Na2HPO4·2H2O diluted with distilled water to a final volume of 1 liter, pH=7.4 
• Wash Buffer – 0.5% Tween 20 (Sigma, Germany) in PBS 
• Coating Buffer – 1.59 g Na2CO3, 2.93 g NaHCO3 diluted with distilled water to end 
volume of 1 liter, pH=9.6 
• Incubation Buffer – 1% fat-free BSA (Sigma, Germany) + 0.01% thimerosal in 
PBS 
• TMB substrate (Calbiochem, Germany) 
• Stop Solution – 2M sulfuric acid 
 
Test Preparation 
• Calibrator Reconstitution – The calibrator was reconstituted with 500µl distilled 
water to get a stock solution of 132.7 ng/ml. Then it was kept at room temperature for 
at least 15 minutes with gentle agitation. Meanwhile, 4 microcentrifuge tubes with 100 
µl incubation buffer were prepared. Then 100µl stock solution was used to make a 
series of dilution (66.35 ng/ml, 33.18 ng/ml, 16.59 ng/ml and 8.29 ng/ml). The 
incubation buffer served as a standard of 0 ng/ml.  
• Supernatant Sample – Supernatants stored at -20°C were thawed at room 
temperature. Supernatants collected from HES, 12Z, THESC and 22B were diluted 
10-fold, 20-fold, 25-fold and 50-fold with incubation buffer, respectively.   
• Coating Plate – The coating antibody was reconstituted with 500 µl distilled water. 
Then 100 µl of coating antibody was mixed thoroughly with 10 ml coating buffer. This 
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solution (100 µl) was pipetted into each well of a 96-well ELISA plate. The plate was 
incubated over night (at least for 16 hours) at 4°C .  
• Diluting Conjugate Solution – The conjugate solution was stored as a 50x 
concentrated solution. The conjugate solution was diluted 1:50 with incubation buffer 
prior to use.  
  
Assay Procedure 
All reagents and samples were brought to room temperature before use. All samples, 
standards and controls were assayed in duplicate. The procedure of the assay is 
described in Figure 10. 
 30 
 
 
 
Prepare the reagents and the samples as described above 
Add 100 µl incubation buffer into each well. 
Discard the liquid phase and wash all wells with 200 µl wash buffer. 
Repeat 2 times. 
Add 25 µl sample or standard with 75 µl incubation buffer into each well  
Discard the liquid in all wells thoroughly.  
Without washing, add 100 µl conjugate working 
solution into each well. 
Remove the coating antibody  
 Incubate 1 hour at 37°C  
 Incubate 1 hour at 37°C  
 Incubate 1 hour at 37°C  
Add 100 µl TMB substrate into each well. 
Incubate for 10 min at RT.  
Protect from light.  
Add 100 µl Stop Solution to each well. 
Measure the OD values at 450 nm on a 
microplate reader, with the correction 
wavelength at 570 nm. 
Figure 10. Scheme of PAI-1 ELISAs  
 within 10 min. 
Discard the liquid phase and wash all wells with 200 µl wash buffer. 
Repeat 2 times. 
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2.5 Cell Adhesion Assay 
To analyse the effect of PAI-1 on cell adhesion, a cell adhesion assay was performed. 
The procedure of this assay is described briefly in Figure 11. Three independent 
experiments were performed. 
 
 
 
 
 
 
 
 
Prepare cell suspension (1x106 cells/ml) with medium 
containing 1% FCS in falcon tubes. 
Add PAI-1 to different final 
concentration. Add PAI-1 dissolving buffer 
Add 1 ml cell suspension with or without PAI-1 into 6-well plates. 
Incubate at 37°C and control the process of cell 
adhesion under a microscope. 
after 4 hours 
Remove the medium. 
Wash each well 2 times with 1 ml 1x Dulbecco’s PBS with Ca2+ and Mg2+ 
Measure the cell quantity in each well with 
CASY counter. 
Figure 11. Procedure of the cell adhesion assay after treating cells withPAI-1 
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2.5.1 Cell Stimulation with PAI-1 
• recombinant active mutant human PAI-1 (American diagnostica, U.S.A.)  
stock concentration=40 µM  
The cell pellets of all four cell types studied were obtained by following the procedure 
which was described in section 2.2.4. Cell pellets were re-suspended with medium 
containing 1% FCS. Then the cell numbers were measured and several tubes of cell 
suspensions containing 1X106 cells/ml were prepared. Then active rh-PAI-1 was 
added into the corresponding cell suspension at final concentrations of 40 nM, 20 nM, 
10 nM or 5 nM, respectively. Buffer (50 mM NaH2PO4, 150 mM NaCl, 1 mM EDTA, 
pH=6.6) used to dissolve PAI-1 was used as a negative control. Then 1 ml cell 
suspension with or without PAI-1 was transferred into 6-well cell culture plates, 
respectively. The cell culture plates were cultured (37°C, 5% CO 2) for 4 hours.  
 
 
2.5.2 Determining the Number of Adherent Cells 
The process of cell adhesion was controlled under a microscope every hour. After 4 
hours, nearly all cells in the control wells were attached on the culture plates. Then 
the medium was removed. Dulbecco’s PBS with Ca2+ and Mg2+ (1x, PAA, Austria) 
was used to wash 2 times in order to remove the residual medium and detached cells. 
Then 500 µl accutase was added into each well and the cell culture plates were 
incubated at 37°C until all cells were detached. Th e detachment of cells was 
controlled microscopically. Then 500 µl fresh and warm medium was added into each 
well to neutralize the accutase. Thereafter, 10 µl cell suspension was transferred to a 
CASY tube with 10 ml CASY ton solution and mixed thoroughly. Then the cell 
numbers were measured with the CASY-counter.  
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2.6 Analysis of the Phospho-EGF Receptor Level after TGF-β Stimulation 
To investigate whether the EGF receptor is phosphorylated by TGF-βs in endometrial 
and endometriotic cells, PathScan® ELISAs were performed. The procedure is 
described briefly in Figure 12. 
 
 
 
 
 
 
Seed 1x106 cells in 60 mm dishes with media containing 10% FCS 
Add TGF-β1 or TGF-β2 (10 ng/ml), respectively 
Remove medium and add cell lysis buffer 
Scrape cells and transfer cells to the 
eppendorf tube with lysis buffer 
Sonicate the cell suspension briefly 
 after 6 hours  
 over night 
Replace medium with 10% FCS to medium with 1% FCS 
 after 5 min., 15 min., 30 min. or 60 min.  
Figure 12. Scheme for analyzing EGF receptor phosphorylation. 
after 5 min., on ice  
Perform phospho-EGF receptor PathScan® ELISAs 
Spin for 10 min. at 14000 x g at 4°C 
Collect the supernatants and store them at -80°C 
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2.6.1 Cell Homogenate 
• 1x Cell Lysis Buffer (Cell Signaling Technology®) : 20 mM Tris (pH 7.5), 150 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4 and 1 µg/ml leupeptin. 
 
After stimulation with TGF-βs, medium was removed from the cell culture dishes and 
all procedures afterwards were performed on ice. Ice cold PBS was added to remove 
the residual medium. The cell lysis buffer was kept on ice and mixed with 1 mM 
phenylmethylsulfonyl fluoride (PMSF) prior to use. Cell lysis buffer (300 µl) was 
added into each dish. After incubating on ice for 5 minutes, cells were scraped off 
and transferred into a 2 ml eppendorf tube with cell lysis buffer. Then the cell lysates 
were sonicated for 1 minute (pulsed, 40% of max power, 40% duty cycle) by using 
Sonifier® cell disruptor B15 (Branson Ultralsonics Corp., USA). After that, the cell 
lysates were centrifuged (14000 x g, 10 minutes at 4°C). Then the supernatant from 
each tube was transferred into a new eppendorf tube and stored at -80°C.  
 
 
2.6.2 PathScan® Phospho-EGF Receptor ELISAs 
PathScan® ELISA kits targeting three different phosphorylation sites of the EGF 
receptor (Tyr845, Tyr1068, Tyr1173) were used to test the level of phospho-EGF 
receptor in the cell lysates (Hackel et al., 1999; Zwick et al., 1999).  
The kits contained: 
• EGF Receptor mAb coated microwells (96 tests) 
• P-EGF Receptor (Tyr845, Tyr1068, Tyr1173) Detection Antibodies 
• Anti-rabbit IgG, HRP-linked Antibody 
• TMB Substrate 
• Stop Solution 
• Sample Diluent Buffer 
• ELISA Wash Buffer (20X): This buffer was diluted to 1X buffer with purified water 
prior to use. 
• Cell Lysis Buffer (10X) 
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Assay Procedure 
All reagents and samples were brought to room temperature before use. The 1X cell 
lysis buffer was used as the blank sample. All samples were assayed in duplicate. 
The procedure of the assay is described in Figure 13. 
 
 
Add 100 µl of each sample to the appropriate well 
Add 100 µl of Detection Antibody to each well  
Discard liquid phase and wash all wells with 200 µl 1X wash buffer, 
repeat 4 times 
 Incubate overnight at 4°C  
 Incubate 1 hour at 37°C  
Add 100 µl of HRP-linked Antibody to each well 
 Incubate 30 minutes at 37°C 
Add 100 µl TMB substrate into each well. 
Incubate 10 minutes at 37°C  
Add 100 µl Stop Solution to each well. 
Measure the OD values at 450nm on a 
microplate reader, with the correction 
wavelength at 570nm. 
Figure 13. Scheme of PathScan® Phospho-EGF Receptor ELISAs 
 within 30 min. 
Discard liquid phase and wash all wells with 200 µl 1X wash buffer, 
repeat 4 times 
Discard liquid phase and wash all wells with 200 µl 1X wash buffer, 
repeat 4 times 
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2.7 Analysis of the Localization of Phospho-ERK1/2 after Stimulation with TGF-
βs in Endometrial and Endometriotic Cells 
To investigate whether TGF-βs stimulate phosphorylation of ERK1/2, the intracellular 
localization of phospho-ERK1/2 in endometrial and endometriotic cells was evaluated. 
The procedure is described briefly in Figure  14. 
  . 
 
 
 
 
 
2.7.1 Pre-treatment with TGF-βs 
Cells were counted as described in 2.2.7. Then 1x105 cells were seeded into each 
well of a 24-well Imaging Plate FC (Zell-Kontact, Germany), which is designed 
specially for immunofluorescence, with 1 ml medium containing 10% FCS. The cells 
were cultured (37°C, 5% CO 2) overnight. Cells were then starved as described in 
2.2.9 for 6 hours. After that, cells were stimulated with 10 ng/ml TGF-β1 or TGF-β2 
as described in 2.2.10, for 15 minutes. 
 
 
Culture 1x105 cells with 1ml medium (10% FCS) in each well of a 
Imaging Plate FC (24 wells) 
Replace medium (10% FCS) with medium (1% FCS) 
 
Stimulate cells 
with TGF-β1  
Stimulate cells 
with TGF-β2  
6 hours 
15 min. 
Cell immunofluorescence 
Figure 14.  Procedure of phospho-ERK1/2 assay with stimulation with TGF-βs 
Add PBS as 
negative control  
over night 
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2.7.2 Cell Immunofluorescence 
After stimulating with TGF-βs for 15 minutes, the medium was removed. Then a cell 
immunofluorescence assay was performed. The procedure is described in Figure 15. 
The image was evakyated under a confocal microscope (Olympus, Germany). 
 
Reagents preparation: 
• Fixation buffer – ice cold acetone and methanol mixture (1:1) 
• Phosphate buffered saline (PBS) – 8.0 g NaCl, 0.2 g KCl, 0.2 g KH2PO4, 1.44 g 
Na2HPO4·2H2O diluted with distilled water to a final volume of 1 liter, pH=7.4 
• Tris buffered saline Tween-20 (TBST) – 8.0 g NaCl, 0.2 g KCl, 3 g Tris-base, 500 
µl Tween-20 diluted with distilled water to a final volume of 1 liter, pH=7.4 
• Blocking buffer – 3% bovine serum albumin (BSA) in TBST 
• Diluting buffer – 1% bovine serum albumin (BSA) in TBST 
• First antibody – phospho-ERK1/2 antibody (Cell Signaling Technology®), rabbit 
source, 1:200 diluted in diluting buffer 
• Second antibody – goat anti-rabbit IgG labelled with Alexa Fluor® 546 dye 
(Invitrogen), 1:200 diluted in diluting buffer 
• Nuclei staining buffer – Hoechst-nuclei staining dye (Invitrogen), 1:1000 diluted in 
PBS 
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Add 200 µl fixation buffer to each well 
Empty and wash all wells with PBS for 3 times 
Add blocking buffer into each well 
Remove the blocking buffer 
 Incubate 10 min. at RT  
 Incubate 1 hour at RT 
Without wash, add first antibody into each well 
 Incubate overnight at 4°C 
Add second antibody into each well 
Incubate 1 hour at RT, protect from light  
Empty and wash all wells with PBS for 3 times, protect from light 
Add nuclei staining buffer into each well, protect from light 
Figure 15. Scheme of cell immunofluorescence. 
Empty and wash all wells with PBS for 3 times 
Add 500 µl PBS into each well 
Empty and wash all wells with PBS for 3 times 
Observe under a confocal microscope 
after 15 min. 
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2.8 Statistical Methods  
To analyse the data from the results, statistical analysis was performed. All 
experiments were done at least three times in duplicate, and the data are shown as 
means±SEM.  To analyse the significance of the data, we used the statistic software 
like InStat Graphpad® (www.graphpad.com) and Microsoft Excel and performed the 
test of Kruskal-Wallis, a non-parametric test. 
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3    Results 
 
 
3.1 Influence of TGF-β1 or TGF-β2 on Cell Numbers 
Endometrial and endometriotic cells were treated with TGF-β1 or TGF-β2 (10ng/ml), 
respectively, in order to find out how TGF-βs affect cell numbers and to compare 
endometrial and endometriotic cells. Furthermore, cell numbers were needed to 
standardize the cytokine secretion afterwards.  
The results showed that either TGF-β1 or TGF-β2 reduced the proliferation of both 
endometrial (Fig. 16) and endometriotic cells (Fig. 17) within 72 hours.  Although the 
reduction in cell numbers was modest, it was significant. 
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Figure 16. Quantification of endometrial cells with/without stimulation by TGF-βs. 
The quantity of endometrial epithelial cells (A) was reduced by approximately 13%, 
while the quantity of endometrial stromal cells (B) was reduced by approximately 
A 
B
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10%, after being treated for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), respectively 
(P<0.05, n=9). 
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Figure 17. Quantification of endometriotic cells with/without stimulation by TGF-βs. 
The quantity of endometriotic epithelial cells (A) was reduced by approximately 15%, 
while the quantity of endometriotic stromal cells (B) was reduced by approximately 
11% after being treated for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), respectively 
(P<0.05, n=9).  
 
In summary, either TGF-β1 or TGF-β2 reduced the cell numbers of four different cell 
types in a range from 10% to 15%. However, both TGF-β1 and TGF-β2 did not show 
different effects on cell numbers in endometrial cells and endometriotic cells, neither 
in epithelial cells nor in stromal cells. 
 
B
A
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In the experiments described above, 3x105 cells/well have been seeded initially. 
Interestingly, when the initial cell quantity was lower (3x104 cells/well), TGF-βs 
demonstrated a different effect. TGF-βs increased the cell numbers of endometriotic 
epithelial cells (12Z), in a dose-dependent manner (Fig. 18). Similar results were 
observed in endometrial epithelial cells (HES), endometrial stromal cells (THESC) 
and endometriotic stromal cells (22B) (data not shown).  
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Figure 18. Quantification of cell numbers with different concentrations of TGF-βs or 
without TGF-βs. Endometriotic epithelial cells (12Z) were treated for 72 hours with 
TGF-β1 or TGF-β2 (1 ng/ml, 5 ng/ml, 10 ng/ml), respectively. Cell numbers were 
increased either by TGF-β1 or TGF-β2 dose-dependently (**=P<0.01, ***=P<0.001, 
n=9). 
 
 
3.2 Influence of TGF-β1 or TGF-β2 on MMP-2 Secretion  
MMPs are important in tissue breakdown and cell shedding during menstruation and 
may be involved in the invasiveness of ectopic endometrial tissue (Juhasz-Böss et al., 
2009). TGF-β1 suppresses the production of MMP-3 and MMP-7 in endometrium 
(Bruner et al., 1995) but increases the expression of MMP-2 and MMP-9 (Hirata et al., 
2003). MMP-2 expression is also detected at higher level in the endometrium of 
patients with endometriosis compared to endometrium of women without 
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endometriosis (Chung et al., 2002). Thus, it is important to study the secretion of 
gelatinases and whether TGF-βs affect the production in endometrial or 
endometriotic cells. 
 
 
3.2.1 Basal Secretion of MMP-2 and MMP-9 in Endometrial and Endometriotic 
Cells 
To compare the basal MMP-2 secretion by endometrial and endometriotic cells, 
ELISAs have been performed to quantify the MMP-2 levels of each cell type after cell 
culture for 72 hours. The concentration of MMP-2 was standardized as ng/ml per 
1x107 cells.  
Results showed that endometrial epithelial cells (HES) secreted only very low MMP-2 
levels (8 ng/ml), while endometriotic epithelial cells (12Z) secreted 116 ng/ml MMP-2. 
Endometrial stromal cells (THESC) secreted 1403 ng/ml MMP-2 which was much 
higher compared to the epithelial cells. Endometriotic stromal cells (22B), which 
secreted 1726 ng/ml MMP-2, were the most productive of all cell lines studied (Fig. 
19).   
 
Figure 19. Basal secretion of MMP-2 by endometrial and endometriotic cells. Cells 
were cultured for 72 hours without any treatment. Endometriotic epithelial cells (12Z) 
secreted approximately 15-fold more MMP-2 than endometrial epithelial cells (HES). 
Endometriotic stromal cells secreted more MMP-2 compared to endometrial stromal 
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cells (THESC). In general, the stromal cells (THESC and 22B) secreted much more 
MMP-2 compared to the epithelial cells (HES and 12Z).  
 
The MMP-9 secretion was also measured with ELISAs. However, MMP-9 was not 
detected in endometrial cells and also rarely detectable in endometriotic cells after 
being cultured for 72 hours (Fig. 20). Endometriotic epithelial cells (12Z) secreted 5.7 
ng/ml MMP-9 while endometriotic stromal cells (22B) secreted 34.8 ng/ml. However, 
both endometrial epithelial cells (HES) and stromal cells (THESC) secreted no MMP-
9. 
 
Figure 20. Basal secretion of MMP-9 by endometrial and endometriotic cells. Cells 
were cultured for 72 hours without any treatment. Endometrial epithelial cells (HES) 
and endometrial stromal cells (THESC) secreted no MMP-9, while endometriotic 
stromal cells (22B) secreted 6-fold more MMP-9 compared to endometriotic epithelial 
cells (12Z), but secretion was quite low.  
 
In summary, endometriotic cells generally secreted more MMP-2 compared to normal 
endometrial cells. Stromal cells still contributed the most to MMP-2 secretion in 
normal endometrial cells as well as in endometriotic cells.  However, MMP-9 was 
much less secreted compared to MMP-2. MMP-9 was even not detectable in 
endometrial cells.  
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3.2.2 Analysis of Smad-dependent and Smad-independent TGF-β-induced 
MMP-2 Secretion  
To investigate whether TGF-βs regulate MMP-2 secretion, endometrial and 
endometriotic cells were treated for 72 hours with 10 ng/ml TGF-β1 or TGF-β2, 
respectively. In the inhibition group, three different inhibitors which target Smad-
dependent or non-Smad-dependent pathways were added 2 hours before adding the 
TGF-βs. In all cell types studied, MMP-2 secretion was increased by TGF-β1 or TGF-
β2, approximately 5 to 6-fold in epithelial cells and 2-fold in stromal cells, compared 
to the control group (P<0.01, n=24) (Figs. 21–26).  
 
  
3.2.2.1 Analysis of the Smad Pathway in MMP-2 Secretion   
The inhibitor LY364947 was used to investigate the role of the Smad-dependent 
pathway in MMP-2 secretion. The inhibitor blocks the phosphorylation of Smad2/3 by 
selectively inhibiting TβR1. LY364947 (5 µM) was added 2 hours before adding the 
TGF-βs (10 ng/ml). Then cells were cultured for 72 hours. The MMP-2 level in the 
supernatants was quantified with ELISAs for MMP-2. 
The results showed that TGF-β1 and TGF-β2 both increased MMP-2 secretion, and 
this elevation was completely blocked by LY364947 in all cell lines. The inhibitor also 
moderately reduced the basal MMP-2 secretion because the FCS in the medium 
contains a small amount of TGF-β1. All results are statistically significant (Figs. 21, 
22). 
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Figure 21. The TβR1 inhibitor (LY364947) completely inhibited the TGF-β1 or TGF-
β2 induced MMP-2 secretion in endometrial and endometriotic epithelial cells. 
(A) The level of MMP-2 in endometrial epithelial cells (HES) was significantly 
increased 6-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), 
respectively (P<0.001, n=8). (B) The level of MMP-2 in endometriotic epithelial cells 
(12Z) was significantly increased 5-fold after treatment for 72 hours with TGF-β1 or 
TGF-β2 (10 ng/ml), respectively (P<0.001, n=8). LY364947 reduced the TGF-β1 or 
TGF-β2 induced secretion of MMP-2 to the control level in both endometrial and 
endometriotic epithelial cells. 
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Figure 22. The TβR1 inhibitor (LY364947) completely inhibited the TGF-β1 or TGF-
β2 induced MMP-2 secretion in endometrial and endometriotic stromal cells. 
(A) The level of MMP-2 in endometrial stromal cells (THESC) was significantly 
increased 2-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), 
respectively (P<0.01, n=8). (B) The level of MMP-2 in endometriotic stromal cells 
(22B) was significantly increased 2-fold after treatment for 72 hours with TGF-β1 or 
TGF-β2 (10 ng/ml), respectively (P<0.001, n=8). LY364947 reduced the TGF-β1 or 
TGF-β2 induced secretion of MMP-2 to control level in both endometrial and 
endometriotic stromal cells. 
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3.2.2.2 Analysis of the ERK Pathway in MMP-2 Secretion 
A highly selective ERK1/2 inhibitor (ERK inhibitor II) was used to study the role of the 
ERK pathway in MMP-2 secretion. The ERK inhibitor II (20 µM) was added before 
adding the TGF-βs (10 ng/ml). Then cells were cultured for 72 hours. The MMP-2 
level in the supernatants was quantified with ELISAs for MMP-2. 
The results showed that TGF-β1 and TGF-β2 both increased MMP-2 secretion. The 
ERK inhibitor II inhibited the TGF-βs-induced MMP-2 secretion by approximately 15-
25% in all cell lines studied (Figs. 23, 24). 
 
 
 
Figure 23. The ERK inhibitor (ERK inhibitor II) moderately inhibited the TGF-β1 or 
TGF-β2 induced MMP-2 secretion in endometrial and endometriotic epithelial cells. 
(A) The level of MMP-2 in endometrial epithelial cells (HES) was significantly 
increased 6-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), 
0
10
20
30
40
50
60
70
80
Ctrl ERK inh. TGF-β1 TGF-β1
+ERK inh.
TGF-β2 TGF-β2
+ERK inh.
M
M
P-
2 
[n
g/
m
l/1
x
10
7  
ce
lls
]
**
* 
**
* * 
n.s. 
0
100
200
300
400
500
600
700
800
Ctrl ERK inh. TGF-β1 TGF-β1
+ERK inh.
TGF-β2 TGF-β2
+ERK inh.
M
M
P-
2 
[n
g/
m
l/1
x
10
7  
ce
lls
] **
* 
**
* 
** n.s. 
A 
B 
 49 
respectively (P<0.01, n=8). The ERK inhibitor moderately inhibited the TGF-β1 or 
TGF-β2-induced MMP-2 secretion in HES (TGF-β1, n.s., n=8; TGF-β2, P<0.05, n=8). 
(B) The level of MMP-2 in the endometriotic epithelial cells (12Z) was significantly 
increased 5-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), 
respectively (P<0.01, n=8). The ERK inhibitor slightly inhibited the TGF-β1-induced 
MMP-2 secretion (approx. 10%, n. s., n=8) and moderately inhibited the TGF-β2-
induced MMP-2 secretion in 12Z (approx. 20%, P<0.05, n=8). 
 
 
 
Figure 24. The ERK inhibitor (ERK inhibitor II) moderately inhibited the TGF-β1 or 
TGF-β2 induced MMP-2 secretion in endometrial and endometriotic stromal cells. 
(A) The level of MMP-2 in endometrial stromal cells (THESC) was significantly 
increased 2-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), 
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respectively (P<0.01, n=8). The ERK inhibitor II moderately inhibited the TGF-β1 or 
TGF-β2 induced MMP-2 secretion in THESC (approx. 20%, n. s., n=8). (B) The level 
of MMP-2 in endometriotic stromal cells (22B) was significantly increased 2-fold after 
treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), respectively (P<0.01, n=8). 
The ERK inhibitor II moderately inhibited the TGF-β1 or TGF-β2-induced MMP-2 
secretion in 22B (approx. 20%, P<0.05, n=8). 
 
 
 
 
3.2.2.3 Analysis of the p38 MAPK Pathway in MMP-2 Secretion 
A highly selective p38 MAP kinase inhibitor (SB203580) was used to study the role of 
the p38 MAPK pathway in MMP-2 secretion. SB203580 (5 µM) was added 2 hours 
before adding the TGF-βs (10 ng/ml). Then cells were cultured for 72 hours. The 
MMP-2 level in supernatants was quantified with ELISAs for MMP-2. 
The results showed that TGF-β1 and TGF-β2 both increased MMP-2 secretion. 
However, SB203580 showed a slight but non-significant effect on inhibition of the 
TGF-β induced MMP-2 secretion in epithelial cells (Fig. 25) and had no effects on the 
stromal cells (Fig. 26). 
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Figure 25. The p38 MAPK inhibitor (SB203580) slightly inhibited the TGF-β1 or TGF-
β2 induced MMP-2 secretion in endometrial and endometriotic epithelial cells. 
(A) The level of MMP-2 in endometrial epithelial cells (HES) was significantly 
increased 6-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), 
respectively (P<0.001, n=8). (B) The level of MMP-2 in endometriotic epithelial cells 
(12Z) was significantly increased 5-fold after treatment for 72 hours with TGF-β1 or 
TGF-β2 (10 ng/ml), respectively (P<0.001, n=8). SB203580 slightly reduced (approx. 
10%) the TGF-β1 or TGF-β2 induced secretion of MMP-2 in both endometrial and 
endometriotic epithelial cells. However, it was not significant. 
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Figure 26. The p38 MAPK inhibitor (SB203580) did not inhibit the TGF-β1 or TGF-β2 
induced MMP-2 secretion in endometrial and endometriotic stromal cells. 
(A) The level of MMP-2 in endometrial stromal cells (THESC) was significantly 
increased 2-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), 
respectively (P<0.01, n=8). (B) The level of MMP-2 in endometriotic stromal cells 
(22B) was significantly increased 2-fold after treatment for 72 hours with TGF-β1 or 
TGF-β2 (10 ng/ml), respectively (P<0.001, n=8). SB203580 showed no effect on the 
TGF-β1 or TGF-β2 induced MMP-2 secretion in both endometrial and endometriotic 
stromal cells.  
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In summary, both TGF-β1 and TGF-β2 increased the secretion of MMP-2 
dramatically in all four cell types studied. However, the extent of elevation was quite 
similar between endometrial and endometriotic cells (HES versus 12Z, THESC 
versus 22B). The TβR1 inhibitor (LY364947) repressed the TGF-β1 or TGF-β2-
induced MMP-2 secretion down to the control level while the p38 MAPK inhibitor 
(SB203580) showed no effect. The ERK inhibitor II showed a moderate effect on 
inhibition of the MMP-2 secretion, which indicated that the Smad pathway was the 
main pathway, but the ERK pathway is also required in order to achieve high level 
secretion of MMP-2. 
 
 
3.3 Influence of TGF-β1 or TGF-β2 on PAI-1 Secretion 
PAI-1 is considered to be one of the gold standards for studying the effects of TGF-
βs on gene expression. Moreover, PAI-1 might play an important role in cell migration 
because PAI-1 detaches cells from the extracellular matrix by inactivating integrins 
(Czekay et al., 2003), which might contribute to the migration of retrograde 
endometrial tissue during the pathological process of endometriosis.  
 
 
3.3.1 Basal Secretion of PAI-1 in Endometrial and Endometriotic Cells 
To compare the basal PAI-1 secretion by endometrial and endometriotic cells, 
ELISAs have been performed to quantify the PAI-1 level of each cell line after cell 
culture for 72 hours. The concentration of PAI-1 was standardized as ng/ml per 1x106 
cells.  
Results showed that endometrial epithelial cells (HES) secreted only 3 ng/ml PAI-1 
which was almost undetectable, while endometriotic epithelial cells (12Z) secreted 
\621 ng/ml PAI-1. Endometrial stromal cells (THESC) secreted 2992 ng/ml PAI-1 
which was much higher compared to both epithelial cells. The endometriotic stromal 
cells (22B) which produced huge amounts of PAI-1 (11994 ng/ml) were the most 
productive among the four cell lines (Fig. 27).  
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Figure 27.  Basal secretion of PAI-1 by endometrial and endometriotic cells. Cells 
were cultured for 72 hours without any treatment. Endometriotic epithelial cells (12Z) 
secreted approximately 200-fold more PAI-1 compared to endometrial epithelial cells 
(HES), while HES nearly secreted no PAI-1. Endometriotic stromal cells (22B) 
secreted 4-fold more PAI-1 compared to endometrial stromal cells (THESC).  
 
In summary, stromal cells (THESC and 22B) secreted much more PAI-1 compared to 
epithelial cells (HES and 12Z). Moreover, endometriotic cells generally secreted more 
PAI-1 compared to normal endometrial cells (12Z versus HES; 22B versus THESC). 
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3.3.2 Analysis of Smad-dependent and Smad-independent TGF-β-induced PAI-1 
Secretion 
To investigate how TGF-βs affect PAI-1 secretion, endometrial and endometriotic 
cells were treated with 10 ng/ml of TGF-β1 or TGF-β2, respectively.  
In all cell types studied, PAI-1 secretion was increased significantly by TGF-β1 or 
TGF-β2, approximately 50-fold in endometrial epithelial cells (HES), 7-fold in 
endometriotic epithelial cells (12Z), two to three-fold in stromal cells (THESC and 
22B), compared to the control group. TGF-β1 was more effective on stimulating PAI-
1 secretion compared to TGF-β2 in epithelial cells but not in stromal cells (Figs. 28–
33). 
 
3.3.2.1 Analysis of the Smad Pathway in PAI-1 Secretion  
The inhibitor LY364947 was used to investigate the role of the Smad-dependent 
pathway in MMP-2 secretion. The inhibitor blocks the phosphorylation of Smad2/3 by 
selectively inhibiting TβR1. LY364947 (5 µM) was added 2 hours before adding the 
TGF-βs (10 ng/ml). Cells were cultured for 72 hours after stimulation with the TGF-βs. 
The results showed that TGF-β1 and TGF-β2 both increased PAI-1 secretion, and 
LY364947 was able to block the TGF-β induced secretion of PAI-1 to control levels in 
all cell lines studied (Figs. 28, 29).   
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Figure 28. The TβR1 inhibitor (LY364947) completely inhibited the TGF-β1 or TGF-
β2 induced PAI-1 secretion in endometrial and endometriotic epithelial cells. 
 (A) The level of PAI-1 in endometrial epithelial cells (HES) was significantly 
increased 50-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), 
respectively (P<0.01, n=6). (B) The level of MMP-2 in endometriotic epithelial cells 
(12Z) was significantly increased 6-fold after treatment for 72 hours with TGF-β1 or 
TGF-β2 (10 ng/ml), respectively (P<0.01, n=6). LY364947 reduced the TGF-β1 or 
TGF-β2-induced secretion of PAI-1 to control levels in both endometrial and 
endometriotic epithelial cells. 
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Figure 29. The TβR1 inhibitor (LY364947) completely inhibited the TGF-β1 or TGF-
β2 induced PAI-1 secretion in endometrial and endometriotic stromal cells. 
(A) The level of MMP-2 in endometrial stromal cells (THESC) was significantly 
increased 2-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), 
respectively (P<0.01, n=6). (B) The level of MMP-2 in endometriotic stromal cells 
(22B) was significantly increased 3-fold after treatment for 72 hours with TGF-β1 or 
TGF-β2 (10 ng/ml), respectively (P<0.01, n=6). LY364947 reduced the TGF-β1 or 
TGF-β2 induced secretion of PAI-1 to control levels in both endometrial and 
endometriotic stromal cells. 
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3.3.2.2 Analysis of the ERK Pathway in PAI-1 Secretion  
A highly selective ERK1/2 inhibitor (ERK inhibitor II) was used to study the role of the 
ERK pathway in PAI-1 secretion. The ERK inhibitor II (20 µM) was added before 
adding the TGF-βs (10 ng/ml). Cells were cultured for 72 hours after stimulation with 
the TGF-βs.  
The results showed that TGF-β1 and TGF-β2 both increased PAI-1 secretion in all 
cell lines studied. The ERK inhibitor II demonstrated a modest repression (approx. 
35% to 50%) of PAI-1 secretion which was induced by TGF-β1 or TGF-β2 in all cell 
lines studied (Figs. 30, 31). 
 
 
Figure 30. The ERK inhibitor (ERK inhibitor II) moderately inhibited the TGF-β1 or 
TGF-β2 induced PAI-1 secretion in endometrial and endometriotic epithelial cells. 
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(A) The level of PAI-1 in endometrial epithelial cells (HES) was significantly increased 
50-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), respectively 
(P<0.01, n=6). The ERK inhibitor moderately inhibited the TGF-β1 or TGF-β2-
induced PAI-1 secretion in HES (approx. 50%, P<0.05, n=6). (B) The level of PAI-1 in 
endometriotic epithelial cells (12Z) was significantly increased 7-fold after treatment 
for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), respectively (P<0.01, n=6). The ERK 
inhibitor moderately inhibited the TGF-β1 or TGF-β2 induced PAI-1 secretion in 12Z 
(appro. 40%, P<0.05, n=6). 
 
 
 
Figure 31. The ERK inhibitor (ERK inhibitor II) moderately inhibited the TGF-β1 or 
TGF-β2 induced PAI-1 secretion in endometrial and endometriotic stromal cells. 
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(A) The level of PAI-1 in endometrial stromal cells (THESC) was significantly 
increased 3-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), 
respectively (P<0.01, n=6). The ERK inhibitor moderately inhibited the TGF-β1 or 
TGF-β2-induced PAI-1 secretion in THESC (approx. 50%, P<0.01, n=6). (B) The 
level of PAI-1 in endometriotic stromal cells (22B) was significantly increased 3-fold 
after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), respectively (P<0.05, 
n=6). The ERK inhibitor slightly inhibited the TGF-β1 or TGF-β2 induced PAI-1 
secretion in 22B (approx. 30%, not significant, n=6). 
 
 
 
3.3.2.3 Analysis of the p38 MAPK Pathway in PAI-1 Secretion   
A highly selective p38 MAP kinase inhibitor (SB203580) was used to study the role of 
the p38 MAPK pathway in PAI-1 secretion. SB203580 (5 µM) was added 2 hours 
before adding the TGF-βs (10 ng/ml). Cells were cultured for 72 hours after 
stimulation with TGF-β1 or TGF-β2. 
The results showed that either TGF-β1 or TGF-β2 increased the PAI-1 secretion. In 
the epithelial cells (HES and 12Z), SB203580 showed a moderate inhibiting effect 
which was not significant (Fig. 32). However, SB203580 did not inhibit the TGF-β 
induced secretion in the two stromal cell lines studied (THESC and 22B, Fig. 33). 
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Figure 32. The p38 MAPK inhibitor (SB203580) moderately inhibited the TGF-β1 or 
TGF-β2 induced PAI-1 secretion in endometrial and endometriotic epithelial cells. 
(A) The level of PAI-1 in endometrial epithelial cells (HES) was significantly increased 
50-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), respectively 
(P<0.05, n=6). SB203580 moderately reduced (approx. 25%) the TGF-β1 or TGF-β2-
induced secretion of PAI-1 in HES. However it was not significant. (B) The level of 
PAI-1 in endometriotic epithelial cells (12Z) was significantly increased 6-fold after 
treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), respectively (P<0.05, n=6). 
SB203580 reduced the TGF-β2 induced secretion of PAI-1 (approx. 20%, P<0.01, 
n=6) and the TGF-β1 induced secretion of PAI-1 (approx. 15%, n. s., n=6) in 12Z. 
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Figure 33. The p38 MAPK inhibitor (SB203580) did not inhibit the TGF-β1 or TGF-β2 
induced PAI-1 secretion in endometrial and endometriotic stromal cells. 
(A) The level of PAI-1 in endometrial stromal cells (THESC) was significantly 
increased 3-fold after treatment for 72 hours with TGF-β1 or TGF-β2 (10 ng/ml), 
respectively (P<0.01, n=6). (B) The level of PAI-1 in endometriotic stromal cells (22B) 
was significantly increased 3-fold after treatment for 72 hours with TGF-β1 or TGF-β2 
(10 ng/ml), respectively (P<0.01, n=6). SB203580 showed no effect on the TGF-β1 or 
TGF-β2 induced PAI-1 secretion in both endometrial and endometriotic stromal cells. 
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In summary, both TGF-β1 and TGF-β2 increased the secretion of PAI-1 dramatically 
in all four cell types studied. The extent of elevation was similar between endometrial 
and endometriotic stromal cells (THESC versus 22B), but quite different between 
endometrial and endometriotic epithelial cells (HES=50-fold versus 12Z=7-fold). The 
TβR1 inhibitor (LY364947) repressed the TGF-β1 or TGF-β2-induced PAI-1 secretion 
down to the control level while the ERK inhibitor II moderately inhibited the TGF-β1 or 
TGF-β2-induced PAI-1 secretion by about 35 to 50% in all four cell lines studied. The 
p38 MAPK inhibitor (SB203580) showed a slight inhibiting effect on TGF-β1 or TGF-
β2-induced PAI-1 secretion in epithelial cells (HES and 12Z), but did not affect the 
stromal cells (THESC and 22B).  
 
 
3.4 Analysis of the ERK1/2 Pathway after Stimulation with TGF-β1 or TGF-β2 
By using ELISAs, we have shown that the ERK1/2 inhibitor decreased the TGF-β-
induced MMP-2 or PAI-1 secretion. However, it is not clear which component of the 
ERK pathway is involved. Therefore, it was important to elucidate the connection of 
the ERK and TGF-β pathways.   
 
 
3.4.1 EGF Receptor Phosphorylation after Stimulation with TGF-β1 or TGF-β2 in 
Endometrial and Endometriotic Cells 
The ERKs are generally phosphorylated by activated EGF receptor (Ramos, 2008). 
Samarakoon et al. (2008) reported that TGF-β1 induced the phosphorylation of the 
EGF receptor leading to PAI-1 expression in vascular smooth muscle cells. 
To investigate whether the EGF receptor is phosphorylated by TGF-βs in endometrial 
and endometriotic cells, PathScan® ELISAs were performed. Cells were treated with 
10ng/ml TGF-β1. Considering that the phosphorylation of the EGF receptor might be 
a fast process, several time points less than 1 hour were chosen (5 min., 15 min., 30 
min., and 60 min.). Cells were collected after treatment and homogenized with cell 
lysis buffer (Cell Signaling Technology®). PathScan® ELISAs targeting three different 
phosphorylating sites of the EGF receptor (Tyr845, Tyr1068, Tyr1173) were then 
performed with the cell homogenates.  
The results showed that the phospho-EGF receptor was not detectable in THESC 
cells at any time point analyzed after treatment with 10 ng/ml TGF-β1 (Fig. 34). 
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Similar experiments were performed with the other three cell lines (HES, 12Z and 
22B) and also with the stimulation of 10 ng/ml TGF-β2. However, the results also did 
not reveal any phosphorylation of the EGF receptor by TGF-βs. 
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Figure 34. Treatment of THESC cells with TGF-β1 did not stimulate phosphorylation 
of the EGF receptor (Tyr845, Tyr1068 or Tyr1173). The THESC cells were treated 
with 10 ng/ml TGF-β1 for 5 min., 15 min., 30 min., or 60 min., respectively.  The OD 
values are shown in the figure with blue (Tyr845), red (Tyr1168) and yellow (Tyr1173) 
bars. The OD values of all samples were close to the blank (<0.1). No phospho-EGF 
receptor was detected and TGF-β1 showed no effect on inducing the phosphorylation 
of the EGF receptor at all time points.   
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3.4.2 Localization of ERK1/2 Phosphorylation after Stimulation with TGF-β1 or 
TGF-β2 in Endometrial and Endometriotic Cells 
Samarakoon et al. (2008) summarized the role of ERKs in the non-Smad signalling in 
TGF-β-induced PAI-1 transcription. Our results also showed that the ERK inhibitor 
moderately repressed the TGF-β-induced PAI-1 and MMP-2 secretion in endometrial 
and endometriotic cells. This indicates that TGF-βs might initiate activation of ERK. 
To investigate whether TGF-βs stimulate the phosphorylation of ERK1/2, the 
intracellular localization of phospho-ERK1/2 in endometrial and endometriotic cells 
was tested with immunofluorescence.  
Cells were treated for 15 minutes with 10 ng/ml TGF-β1 or TGF-β2, respectively. 
Then cells were fixed with ice-cold acetone/methanol (1:1). A high affinity phospho-
ERK1/2 antibody (Cell Signaling Technology®) was used as first antibody. A goat 
anti-rabbit IgG labelled with Alexa Fluor® 546 dye (Invitrogen) was used as second 
antibody. Hoechst dye (Invitrogen) was used to stain the nuclei.  All pictures were 
taken with a confocal microscope. The results are shown in the figures below (Figs. 
35, 36, 37, 38).  
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A (neg. ctrl.)                                                      B (ctrl.) 
    
C (+ TGF-β1)                                                 D (+ TGF-β2) 
Figure 35. Treatment with TGF-β1 or TGF-β2 resulted in the phosphorylation of 
ERK1/2 in endometrial epithelial HES cells. Cells were treated for 15 minutes with 10 
ng/ml TGF-β1 or TGF-β2, respectively. No staining was observed in the negative 
control (A). The cytoplasm of very few cells was stained weakly in the untreated 
control group (B). In the TGF-β1 (C) or the TGF-β2 (D) stimulation group, the 
cytoplasm of cells was much stronger stained compared to the untreated control 
group. Moreover, a strong staining was observed both inside and next to the nuclei.  
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                            A (neg. ctrl.)                                                 B (ctrl.) 
    
C (+ TGF-β1)                                                   D (+ TGF-β2) 
Figure 36. Treatment with TGF-β1 or TGF-β2 resulted in the phosphorylation of 
ERK1/2 in endometriotic epithelial 12Z cells. Cells were treated for 15 minutes with 
10 ng/ml TGF-β1 or TGF-β2, respectively. No staining was observed in the negative 
control (A). In the cells without TGF-β treatment (B), there was a moderate staining 
in the cytoplasm and the nuclei. However, the cells were much stronger stained in the 
cytoplasm and nuclei either in the TGF-β1 (C) or the TGF-β2 (D) stimulation group, 
compared to the untreated control group. The staining was mostly concentrated in 
the nuclei and the cytoplasm next to the nuclei.  
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A (neg. ctrl.)                                                      B (ctrl.) 
    
                      C (+ TGF-β1)                                                 D (+ TGF-β2) 
Figure 37. Treatment with TGF-β1 or TGF-β2 resulted in the phosphorylation of 
ERK1/2 in endometrial stromal THESC cells. Cells were treated for 15 minutes with 
10 ng/ml TGF-β1 or TGF-β2, respectively. Weak background staining was observed 
in the negative control (A). In the cells without TGF-β treatment (B), there was a 
weak staining in the cytoplasm and the nuclei. However, the cells were much 
stronger stained in the cytoplasm and nuclei either in the TGF-β1 (C) or the TGF-β2 
(D) stimulation group, compared to the untreated control group and the staining was 
more intense in some nuclei. 
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                          A (neg. ctrl.)                                                    B (ctrl.) 
    
                        C (+ TGF-β1)                                                D (+ TGF-β2) 
Figure 38. Treatment with TGF-β1 or TGF-β2 resulted in the phosphorylation of 
ERK1/2 in endometriotic stromal 22B cells. Cells were treated for 15 minutes with 10 
ng/ml TGF-β1 or TGF-β2, respectively. Weak background staining was observed in 
the negative control (A). In the cells without TGF-β treatment (B), there was a 
moderate staining in the cytoplasm and weak staining in the nuclei. However, the 
cells were much stronger stained in both cytoplasm and nuclei either in the TGF-β1 
(C) or the TGF-β2 (D) stimulation group, compared to the untreated control group. 
The staining was more intense in some nuclei and the cytoplasm next to the nuclei. 
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In summary, without the stimulation of TGF-βs, phospho-ERK1/2 was slightly 
detectable in endometriotic epithelial 12Z cells, endometrial stromal THESC cells and 
endometriotic stromal 22B cells, but not in the endometrial epithelial HES cells. Most 
of the phospho-ERK1/2 dispersed slightly in the cytoplasm and was rarely found 
inside the nuclei. After TGF-β1 or TGF-β2 stimulation, phosphorylation of ERK1/2 in 
all four cell types studied was strongly enhanced and the localization of phospho-
ERK1/2 was mostly detected in the nuclei and the cytoplasm next to the nuclei.  
 
 
 
3.5 Influence of PAI-1 on Cell Adhesion 
One report showed that PAI-1 inhibited the cell attachment to the ECM (fibronectin 
and type I collagen) by inhibiting urokinase receptor-vitronectin and integrin-
vitronectin interaction (Czekay et al., 2003). Considering that TGF-βs induce a 
dramatic elevation of PAI-1 in endometrial and endometriotic cells, we hypothesized 
that they might influence cell adhesion via PAI-1.  
To prove our hypothesis, a cell adhesion assay was performed. Cells were stimulated 
with medium containing 5 nM, 10 nM, 20 nM or 40 nM recombinant PAI-1, 
respectively. After 4 hours only the attached cells were quantified with a cell counter.  
The results showed that PAI-1 decreased the number of adherent cells of all cell lines 
studied after 4 hours in a dose-dependent manner (Figs. 39, 40). Already at a 
concentration of recombinant PAI-1 of 20 nM, a substantial effect on cell detachment 
was observable. The numbers of HES cells were reduced by 38% (Fig. 39), while 
THESC cells were reduced by 35% (Fig. 40), 22B cells were reduced by 28% (Fig. 
40) and 12Z cells were reduced by 19% (Fig. 40). 
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Figure 39. PAI-1 dose-dependently inhibited cell adhesion of endometrial and 
endometriotic epithelial cells to the cell culture plate. (A) The numbers of attached 
endometrial epithelial (HES) cells were decreased by 40%, 38%, 23% or 6% after 
treatment for 4 hours with 40 nM, 20 nM, 10 nM or 5 nM PAI-1, respectively. (B) The 
numbers of attached endometriotic epithelial (12Z) cells were decreased by 26%, 
19%, 7% or 2% after treatment for 4 hours with 40 nM, 20 nM, 10 nM or 5 nM 
recombinant PAI-1, respectively. 
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Figure 40. PAI-1 dose-dependently inhibited cell adhesion of endometrial and 
endometriotic stromal cells to the cell culture plate. (A) The numbers of attached 
endometrial stromal (THESC) cells were decreased by 39%, 35%, 19% or 8% after 
treatment for 4 hours with 40 nM, 20 nM, 10 nM or 5 nM PAI-1, respectively. (B) The 
numbers of attached endometriotic stromal (22B) cells were decreased by 31%, 28%, 
15% or 5% after treatment for 4 hours with 40 nM, 20 nM, 10 nM or 5 nM PAI-1, 
respectively. 
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4    Discussion 
 
 
 
As one of the most important growth factors, TGF-βs are involved in cell proliferation, 
differentiation, apoptosis, and motility in various cell types. They also play important 
roles in many biological processes, e.g. protein synthesis, morphogenesis, embryonic 
development, wound healing, inflammation, immune regulation, and tumorigenesis 
(Kaminska et al., 2005; Padua and Massagué, 2009; Taylor, 2009; Santibañez et al., 
2011). 
Because of the increasing importance of TGF-βs in endometriosis and menstruation 
(Oosterlynck et al., 1994; Pizzo et al., 2002; Gaide Chevronnay et al., 2008), TGF-βs 
and their high-affinity receptors are involved in the development and manifestion of 
endometriosis (Omwandho et al., 2010). 
In this study, endometrial and endometriotic cells were compared. We investigated 
biological functions of TGF-β1 and TGF-β2 in endometrial and endometriotic cells. 
Furthermore, we studied the pathways of TGF-β signaling involved in the secretion of 
MMP-2 and PAI-1. Our study investigated not only the Smad pathway, but also the 
Smad-independent pathways of TGF-β signaling in endometrial and endometriotic 
cells for the first time. 
 
 
4.1 Biological Functions of TGF-βs in Endometrial and Endometriotic Cells  
 
4.1.1 Influence of TGF-βs on cell numbers of Endometrial and Endometriotic 
Cells 
The cell number is determined by the rate of proliferation, apoptosis or necrosis 
(Sommer and Rao, 2002). However, the effects of TGF-βs on cell proliferation and 
apoptosis are extremely dependent on cell types and context. TGF-βs trigger 
apoptosis in epithelial cells, but induce proliferation in fibroblasts (Rahimi and Leof, 
2007). Thus, TGF-βs provide signals for either cell survival or cell apoptosis.  
So far, the interaction between TGF-βs pathway and apoptotic pathways still remains 
uncertain. The Smad pathway is the canonical pathway of TGF-β signaling (Roberts, 
1999). Nevertheless, TGF-βs also cooperate with the death receptor apoptotic 
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pathway (Fas, TNF), the mitochondrial apoptotic pathway (Bcl-2) and several 
intracellular apoptotic modulators (JNK, NF-kappaB) (Sánchez-Capelo, 2005). 
Furthermore, the G1 phase of the cell cycle can be delayed by TGF-βs because they 
induce the synthesis of p15 and p21, which block the cyclin-dependent kinases 
(CDKs), and thus inhibit gene expression of c-myc, which is involved in cell cycle 
progression (Hanahan and Weinberg, 2000). 
In endometrial cells, TGF-βs exerted different effects on cell proliferation and 
apoptosis, compared to cells from other organs. Meresman et al. (2003) showed that 
TGF-β1 stimulated the growth of endometrial epithelial cells at low cell numbers, but 
inhibited it at high cell numbers in women with or without endometriosis. In addition, 
Nasu et al. (2005) demonstrated that TGF-βs inhibited proliferation of endometrial 
stromal cells in a dose-dependent manner. However, these two studies reported the 
influence of TGF-βs on cell proliferation by only using a 3H-thymidine incorporation 
assay (Meresman et al., 2003) or an MTT assay (Nasu et al., 2005), but did not count 
the cells directly. 
In our experiments, we directly counted the number of cells. Our results showed that 
TGF-β1 and TGF-β2 influenced the cell number differently according to the initial cell 
number. TGF-βs increased the cell number when the initial cell number was low, 
whereas decreased the cell number when the initial cell number was high. Our 
results are similar to the results provided by Meresman et al. (2003), showing that the 
influence of TGF-βs on cell proliferation might depend on the initial cell numbers. 
However, the influences of TGF-βs on cell numbers are similar in all four cell types 
studied.  
In addition to cell proliferation, apoptosis or necrosis, also cell adhesion could 
influence cell numbers as will be discussed in the following paragraph. 
 
 
4.1.2 The role of TGF-βs in retrograde menstruation 
According to Sampson’s theory of retrograde menstruation, endometriotic tissues 
originate from retrograde endometrial tissues (Sampson, 1922; 1927). The process 
includes the contraction of the uterus, cell shedding, migration, ectopic cell survival 
and invasion (Omwandho et al., 2010).  
The highest expression of TGF-βs in endometrial tissues was described during the 
late secretory phase and menses (Gaide Chevronnay et al., 2008). Furthermore, 
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TGF-β1 induced an impaired contraction of the uterus (Nasu et al., 2005). These 
results suggest that overexpression of TGF-βs might cause an increased menstrual 
tissue breakdown and retrograde movement of endometrial tissue fragments. 
Endometrial cells are adherent cells that bind to components of the ECM (Klemmt et 
al., 2007). The process of cell-to-ECM adhesion is regulated by specific cellular 
adhesion molecules (CAMs). Typical examples for CAMs are integrins, a group of 
transmembrane proteins, which connect cells to the ECM, such as fibronectin and 
collagens (Witz et al., 2003). Preliminary results obtained in the present study with 
recombinant proteins coated on cell culture plates indicated that all four cell lines 
studied adhered primarily onto fibronectin, collagen I and collagen IV (data not 
shown).  
Koth et al. (2007) showed that integrins can activate latent TGF-β1. However, so far 
there is no evidence that TGF-βs could affect cell adhesion directly in the 
endometrium. The regulation might be indirect. High levels of MMP-2 might trigger 
shedding of endometrial cells by reducing the attachment of cells to the ECM 
because MMP-2 degrades the ECM (Matrisian and Hogan, 1990). Czekay et al. 
(2003) reported that PAI-1 inhibited the cell attachment to the ECM components, 
fibronectin and type I collagen, by inhibiting uPAR-vitronectin and integrin-vitronectin 
interaction. These data suggest that PAI-1 and MMP-2 negatively affect the cell-to-
ECM connection.   
In our experiments, we demonstrated that secretion of both, PAI-1 and MMP-2, was 
dramatically increased by TGF-βs in endometrial and endometriotic cells. Thus, we 
supposed that TGF-βs might reduce cell adhesion and increase cell shedding by 
elevating the levels of MMP-2 and PAI-1. In this case, together with inducing the 
contraction of the uterus, TGF-βs might facilitate retrograde movement of the 
endometrial tissue fragments. 
On the other hand, high levels of TGF-βs might increase the survival potential of 
ectopic endometrial cells. TGF-β1 suppressed the immune system, which was 
demonstrated by lethal multi-organ inflammation in gene knockout mice (Shull et al., 
1992). Furthermore, TGF-β1 suppressed proliferation and differentiation of 
lymphocytes including cytolytic T cells, natural killer cells and macrophages (Pardali 
and Moustakas, 2007). Blocking TGF-β1 function increased the levels of IFN-γ and 
IL-10, which are secreted by natural killer cells derived from human endometrium 
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(Eriksson et al., 2004). Thus, high levels of TGF-βs may trigger immune escape, 
which might decrease the response of natural killer cells to the ectopic tissues. 
   
 
4.2 Differences between Endometrial and Endometriotic Cells 
Sampson’s theory of retrograde menstruation is the most widely accepted (Jensen 
and Coddington, 2010). However, this theory is not able to explain why most women 
can have retrograde menstruation, but not all of them develop endometriosis. The 
different characteristics of ectopic endometrial tissues and eutopic endometrial 
tissues might be one possibility to answer this question. Compared to normal 
endometrial tissues, endometriotic tissues generally show more capability in 
metastasis, implantation, invasiveness and proliferation (Liu and Lang, 2011).      
Banu et al. (2008) analyzed the expression of several genes associated with steroid 
synthesis, cell cycle regulation, ECM degradation, angiogenesis, cell growth, cell 
death and cytokine production. They showed that the genes, which are positively 
associated with metastasis, implantation, invasiveness and proliferation, are 
expressed stronger in endometriotic cells, compared to endometrial cells. 
In our study, we tested the basal secretion of MMP-2, MMP-9 and PAI-1 in vitro. Our 
results also showed clear differences between endometrial and endometriotic cells. 
As shown in the following paragraphs, endometriotic cells produced more MMP-2, 
MMP-9 and PAI-1, compared to endometrial cells, either in epithelial cells as well as 
in stromal cells. 
   
 
4.2.1 MMP-2 and MMP-9 Secretion in Endometrial and Endometriotic cells 
The function of MMPs is mainly the degradation of extracellular matrix, which is 
involved in the shedding process of cells during menstruation and contributes to the 
invasiveness of ectopic endometrial cells (Juhasz-Böss et al., 2009). However, TGF-
βs, which are highly expressed during menses (Gaide Chevronnay et al., 2008), 
mediate the suppression of mRNA expression of stromelysin (MMP-3) and matrilysin 
(MMP-7) in the endometrium (Bruner et al., 1995), but increase the expression of 
gelatinases, MMP-2 and MMP-9 (Hirata et al., 2003). High expression of MMP-2 was 
also detected in the endometrium of patients with endometriosis (Chung et al., 2002) 
and in an endometriosis model with transplanted human endometrial tissue into rat 
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peritoneum (Sotnikova et al., 2010). These data suggest an important role of 
gelatinases in the pathogenesis of endometriosis. However, they did not test MMP-2 
or MMP-9 expression in epithelium or stroma separately.    
In this study, we measured the basal secretion of MMP-2 and MMP-9 in endometrial 
and endometriotic cells in vitro. We found that endometriotic cells generally secreted 
more MMP-2 and MMP-9, compared to endometrial cells. Similar results were shown 
by other investigators in mRNA and activity levels. Banu et al. (2008) showed that the 
mRNA expression and the activity of MMP-2 and MMP-9 in endometriotic cells were 
stronger, compared to normal endometrial cells.  Since MMP-2 and MMP-9 have 
been well documented to be involved in cell invasiveness and metastasis (Giannelli 
et al., 2002; Giannelli and Antonaci, 2002), we suppose that endometriotic cells might 
be more migratory and invasive, compared to normal endometrial cells. In normal 
endometrial cells, epithelial cells nearly secrete no MMP-2, whereas stromal cells 
secrete a lot, thus suggesting that MMP-2, which influence tissue breakdown, is 
mainly secreted by stromal cells. However, in the case of endometriotic cells, the 
epithelial cells were able to secrete a moderate amount of MMP-2. It suggests that 
not only the endometriotic stromal cells, but also the endometriotic epithelial cells 
might also contribute to the ECM degradation and migration/invasion of endometriotic 
tissues during retrograde menstruation.  
The MMP-9 secretion was much lower compared to MMP-2 secretion in all cell lines 
studied. It suggests that the role of MMP-9 might be limited in the pathogenesis of 
endometriosis. However, MMP-9 is detectable in endometriotic cells after all but not 
in endometrial cells, which might contribute to the different characteristics of 
endometriotic cells and endometrial cells.  
Furthermore, MMP-2 and MMP-9 in the endometrium or endometriosis might not only 
be secreted by endometrial cells. Macrophages also secrete large amounts of 
various MMPs (Goetzl et al., 1996). As immune cells, macrophages take part in the 
development of endometriosis (Weiss et al., 2009). Thus, macrophages might be 
another possible source of MMP-2 and MMP-9 in the endometrium or endometriosis. 
 
 
4.2.2 PAI-1 Secretion in Endometrial and Endometriotic cells 
PAI-1 is the major inhibitor of both tissue-type plasminogen activator (tPA) and 
urokinase-type plasminogen activator (uPA). They are both involved in tissue 
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degradation and remodeling (Zorio et al., 2008). Bruse et al. (1998, 2003) showed 
that the expression of PAI-1 and uPA were much higher in the endometriotic and 
endometrial tissue of women with endometriosis, compared to endometrial tissue of 
women without endometriosis. The PAI-1 levels were higher in ectopic tissues than in 
eutopic tissues of the same woman (Bruse et al., 2003). These data strongly 
suggests an important role of PAI-1 in endometriosis. Czekay et al. (2003, 2011) 
showed that cell migration was regulated by uPA and its high affinity receptor, uPAR. 
They demonstrated that PAI-1 perturbed cell attachment to the ECM by inhibiting 
uPAR-vitronectin and integrin-vitronectin interactions, and suggested that PAI-1 
facilitates cell migration by regulating ECM proteolysis. 
In this study, we compared the basal secretion of PAI-1 in endometrial and 
endometriotic cells in vitro. We found that endometriotic cells generally secreted 
more PAI-1 than endometrial cells. Our results showed an increased PAI-1 synthesis 
in endometriotic cells compared to endometrial cells, which corresponds to the result 
of increased PAI-1 expression that was observed in endometriotic tissues (Bruse et 
al., 2003). It suggests that endometriotic cells might be more potent to migrate, 
compared to normal endometrial cells. Secretion of PAI-1 in normal endometrial 
tissue might mostly rely on stromal cells since the endometrial epithelial cells secrete 
nearly no PAI-1. However, in endometriotic tissues, PAI-1 secretion is contributed by 
both epithelial and stromal cells, because the endometriotic epithelial cell can secrete 
a moderate amount of PAI-1.  
 
 
4.3 TGF-β Signaling in Endometrial and Endometriotic Cells 
Among all the pathways, the Smad-dependent pathway is considered to be the 
primary pathway of TGF-β signaling, which is activated by the phosphorylation of 
TβRI on serine/threonine (Massagué and Wotton, 2000). After being phosphorylated, 
TβRI propagates the signal to downstream substrates, mostly Smad2/3 (Massagué 
and Wotton, 2000). In addition to the Smad-dependent pathway, there are Smad-
independent pathways, which are also activated by the TGF-β receptors 
(Kretzschmar et al., 1997; Lee et al., 2007; Zhang et al., 2009).  
In our studies, we demonstrated a TGF-β-induced MMP-2 and PAI-1 secretion in 
endometrial and endometriotic cells. Furthermore, by using specific inhibitors 
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targeting downstream cascades of TGF-β signaling, both Smad-dependent and 
Smad-independent pathways were studied. 
 
 
4.3.1 The Smad-dependent Pathway in TGF-β Signaling 
The transducers of the Smad-dependent pathway include the receptor regulated (R-) 
Smads (Smad1, 2, 3, 5 and 8), the common mediator (co-) Smad (Smad4) and 
inhibitory (I-) Smads (Smad6 and 7). Generally, signals from TGF-βs are mediated 
through Smad2 and Smad3 (Shimizu et al., 1998). However, Kang et al. (2009) 
reported that TGF-β can transiently activate Smad1 and Smad5 as well.  
In our study on the Smad-dependent pathway, we used a TβRI inhibitor (LY364947) 
that specifically blocks the kinase activity of the TβRI and thus also the 
phosphorylation of Smad2 and Smad3 (Sawyer et al., 2003). Our results showed that 
LY364947 can completely inhibit the TGF-β-induced secretion of both MMP-2 and 
PAI-1 in endometrial and endometriotic cells. Unpublished results of our group 
showed that a specific Smad3 inhibitor (SiS3) inhibited the TGF-β-induced secretion 
of PAI-1, partially but not completely, thus, suggesting also the involvement of Smad2 
in TGF-β signaling. These data support the fact that Smads are the most important 
mediators of TGF-β signaling from the receptors to the nucleus.   
 
 
4.3.2 The Smad-independent Pathways in TGF-β Signaling 
Zhang et al. (2009) summarized the non-Smad pathways, which reinforce or 
modulate the signal transduction of the TGF-βs. In several in vitro studies on cell 
models, the small GTPase Ras and the extracellular signal-regulated kinases (ERKs), 
p38 mitogen-activated protein kinase (p38 MAPK) and c-Jun N-terminal kinases 
(JNKs) are found to be implicated in TGF-β signaling (Yue and Mulder, 2000). 
Furthermore, they are suggested to interact with the Smad-dependent pathway 
(Massague et al., 2000; Moustakas and Heldin, 2005). The ERK pathway can lead to 
direct phosphorylation of R-Smads, blocking their nuclear translocation and 
transcriptional output (Kretzschmar et al., 1997). The p38 substrate kinase, mitogen 
and stress activated protein kinase-1 (MSK1) regulates the transcriptional activity of 
Smad3 by promoting its association with the co-activator p300 (Abécassis et al., 
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2004). In addition, TGF-β-activated JNK phosphorylate Smad3 and induce its nuclear 
translocation and transcriptional activity (Engel et al., 1999). 
In our studies on the non-Smad-dependent pathways, we used an ERK inhibitor, 
which specifically inhibits the activity of ERK1 and ERK2 (Ohori et al., 2005), and 
SB203580, a p38/MAPK inhibitor (Roux and Blenis, 2004). Our results showed that 
the ERK inhibitor moderately inhibited the TGF-β-induced secretion of MMP-2 and 
PAI-1 in endometrial and endometriotic cells. SB203580 showed a slight inhibiting 
effect on the TGF-β-induced secretion of MMP-2 and PAI-1 in epithelial cell, whereas 
it showed no effect on stromal cells. Our results suggest that ERKs are involved in 
the TGF-β-induced gene transduction in endometrial and endometriotic cells, 
whereas p38/MAPK seems to be only slightly involved in the TGF-β-induced gene 
transduction in epithelial cell, but not in stromal cells.  
Furthermore, we studied the intracellular localization of phospho-ERK1/2 in 
endometrial and endometriotic cells. Our results showed that, without TGF-β 
stimulation, phospho-ERK1/2 is expressed slightly in endometrial stromal cells and 
endometriotic cells (22B>THESC>12Z), but not in endometrial epithelial cells. 
Furthermore, expression of phospho-ERK1/2 is enhanced rapidly by the stimulation 
of TGF-βs and accumulated in and around the nucleus, thus suggesting that 
phospho-ERK1/2 is translocated from the cytoplasm to the nucleus after TGF-β 
stimulation. These results corroborate the results obtained with the ERK inhibitor, that 
ERKs are involved in the TGF-β induced MMP-2 and PAI-1 gene transcription in 
endometrial and endometriotic cells. 
Because our results demonstrated besides the Smad pathway, the involvement of 
the ERK pathway in TGF-β signaling in endometrial and endometriotic cell lines, it 
was important to elucidate the connection between the TGF-β-induced Smad 
pathway and ERK pathway. With respect to the Smad pathway, TGF-β signals 
through its cell surface receptor (TβRI), which phosphorylates Smad2 or Smad3. 
Then Smad2/3, together with Smad4, binds to the Smad binding elements (SBEs) or 
transcription factor E3 (TFE3) (Hua et al., 1999; Massagué and Wotton, 2000).  
Unlike the Smads, the phosphorylation of ERKs requires the activation of tyrosine 
kinases on the cell surface receptors, such as the EGF receptor. The activated 
tyrosine kinases phosphorylate growth factor receptor-bound protein-2 (GRB2) and 
(son of sevenless) SOS, which then activate the Ras cascades including the ERKs 
(Dance et al., 2008). Samarakoon et al. (2008) demonstrated that the activation of 
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ERKs leading to PAI-1 transcription required the phosphorylation of the EGF receptor 
by TGF-β1 in vascular smooth muscle cells. Therefore, we performed PathScan® 
ELISAs targeting the phospho-EGF receptor on three different tyrosine sites. 
However, the phospho-EGF receptor was not detectable in endometrial and 
endometriotic cells after TGF-β stimulation. Hence, TGF-βs does not activate ERKs 
via the EGF receptor in endometrial and endometriotic cells.  
Other possibilities were shown by Lee et al. (2007), who demonstrated that TβRI 
directly phosphorylated ShcA, which induced the association with GRB2 and SOS, 
then leading to a sequential activation of Ras, Raf, MEK1/2 and ERK1/2. Besides, 
Suzuki et al. (2007) demonstrated that TGF-β activated the Ras-dependent ERK 
phosphorylation through the activation of p21 activated kinase-2 (PAK2). These data 
showed that TGF-β could directly activate the ERKs without participation of the Smad 
pathway. Because we could not find any EGF receptor phosphorylation in 
endometrial and endometriotic cells, thus we suppose that the ERKs might be 
activated by TGF-βs via Grb2/SOS, but this needs to be explored further.  
 
 
4.4 Conclusions 
In this study, we demonstrated the influence of TGF-βs on endometrial and 
endometriotic cell lines in vitro. We found that the endometriotic cells secreted more 
MMP-2, MMP-9 and PAI-1, compared to normal endometrial cells. We showed that 
TGF-βs dramatically increased secretion of MMP-2 and PAI-1 in endometrial and 
endometriotic cells. We also showed that PAI-1 reduced the cell attachment of all 
four cell lines studied. From our data, we suppose that the TGF-β-induced increase 
in PAI-1 and MMP-2 secretion might play a role in increased tissue breakdown during 
menstruation and the increased invasiveness during ectopic endometrial implantation. 
We confirmed that the Smad pathway was the main pathway of TGF-β signaling in 
endometrial and endometriotic cells. Furthermore, we demonstrated for the first time 
the participation of the ERK pathway, a mainly Smad-independent pathway, in TGF-β 
signaling in endometrial and endometriotic cells. However, more experiments are still 
required to clarify the connection between ERKs and TGF-β, as well as the crosstalk 
between Smads and ERKs. Nevertheless, our findings might provide new clues on 
studying or understanding the role of TGF-βs in the pathogenesis of endometriosis. 
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5    Summary 
 
 
 
 
Endometriosis is a chronic pathological disorder in which endometrial-like cells are 
found outside the uterine cavity. TGF-βs were observed to be highly expressed in the 
peritoneal fluid of patients with endometriosis, as well as in endometriotic sites. Thus, 
TGF-βs may play an important role in the pathogenesis of endometriosis. In this 
study, our aim was to investigate the biological function and signal transduction of 
TGF-βs in endometrial and endometriotic cells in vitro.  
Four different cell lines, endometrial epithelial and stromal cells, endometriotic 
epithelial and stromal cells were used in this study. Cells were treated with or without 
TGF-β1 or TGF-β2, respectively. Then the cell numbers were counted and the 
secretion of MMP-2, MMP-9 or PAI-1 was measured with ELISAs. Also the effect of 
PAI-1 on cell adhesion was tested. By using specific inhibitors targeting downstream 
cascades of TGF-β signaling, both Smad-dependent and Smad-independent 
pathways were studied. In addition, the localization of phospho-ERK1/2 after 
stimulation with TGF-β1 or TGF-β2 was analyzed with immunofluorescence.  
Our results showed in the four cell lines studied: (1) TGF-βs had a dual effect on the 
cell numbers, with increased cell numbers when the initial cell number was low, but 
decreased cell numbers when the initial cell number was high. (2) Endometriotic cells 
secreted more MMP-2, MMP-9 and PAI-1, compared to endometrial cells. TGF-β1 or 
TGF-β2 dramatically increased MMP-2 and PAI-1 secretion in all cell lines studied. (3) 
A TβRI inhibitor completely blocked the TGF-β-induced MMP-2 or PAI-1 secretion. 
An ERK1/2 inhibitor partly blocked it. The p38/MAPK inhibitor had only slight effects. 
(4) TGF-β1 or TGF-β2 enhanced accumulation of phospho-ERK1/2 in the nucleus. (5) 
PAI-1 reduced cell attachment in all four cell lines studied. 
In this study, we demonstrated the influence of TGF-βs on endometrial and 
endometriotic cell lines in vitro. From our data, we suppose that the TGF-β-induced 
increase in PAI-1 and MMP-2 secretion might play a role in increased tissue 
breakdown during menstruation and increased invasiveness during ectopic 
endometrial implantation. We confirmed that the Smad pathway was the main 
pathway of TGF-β signaling also in endometrial and endometriotic cells. Furthermore, 
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we demonstrated for the first time the participation of the ERK pathway, a mainly 
Smad-independent pathway, in TGF-β signaling in endometrial and endometriotic 
cells. This finding might provide new options to comprehend the role of TGF-βs in the 
etiology of endometriosis. However, since it is only a first glimpse into the ERK 
pathway in TGF-β signaling in endometrial and endometriotic cells, more researches 
are required to elucidate the connection between ERKs and TGF-β, as well as the 
crosstalk between Smads and ERKs. 
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